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 Abstract 
The discovery of modern antimicrobials in the early 20
th
 century revolutionized treatment 
of infectious diseases.  Less than 100 years later, antimicrobial resistance has become a global 
threat to public health.  With the rise of antimicrobial resistance, the question that remains to be 
answered is:  Can dosing regimens provide maximal clinical efficacy, yet minimize the 
development of antimicrobial resistance?   
A pharmacokinetic / pharmacodynamic approach was utilized to investigate 
oxytetracycline regimens that would impart efficacy while minimizing the potential for 
resistance development due to plasmid transfer.  An in vitro pharmacodynamic model was used 
to quantify the response of a Pasteurella multocida isolate to two oxytetracycline dosing 
regimens.  The PK/PD index most closely related to efficacy was the Cmax:MIC. 
The in vitro pharmacodynamic model was then used to investigate the effects of 
antimicrobial exposure on plasmid transfer.  A mixed population of oxytetracycline-susceptible 
and resistant bacteria was exposed to two dosing regimens and plasmid transfer was quantified.  
When oxytetracycline concentrations exceeded the MIC of the recipient, development of 
resistance was suppressed.  
The same donor and recipient bacteria were used in an in situ swine model to validate the 
in vitro findings.  Following surgical implantation of porous membrane straws containing the 
mixed bacterial population, animal subjects in the treatment groups received one of two 
oxytetracycline treatments.  Oxytetracycline concentrations in the plasma and interstitial fluid 
were quantified.  Plasmid transfer within the implant membranes was quantified and correlated 
 to pharmacokinetic measures in the animal.  Plasmid transfer rates in the implant membranes did 
not correlate to the investigated pharmacokinetic parameters. 
The study methodologies in this dissertation should serve as a foundation for future 
studies in antimicrobial pharmacokinetic/pharmacodynamic research.  The results presented here 
show that the bacterial response to oxytetracycline can be optimized in a concentration 
dependent manner and that antimicrobial resistance development through plasmid transfer can be 
suppressed in vitro when oxytetracycline concentrations exceed the MIC of the recipient 
bacteria.  These results suggest that a proper balance between clinical efficacy and minimizing 
antimicrobial resistance can be achieved for oxytetracycline through appropriate dosing regimens 
and drug formulations. 
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Abstract 
The discovery of modern antimicrobials in the early 20
th
 century revolutionized treatment 
of infectious diseases.  Less than 100 years later, antimicrobial resistance has become a global 
threat to public health.  With the rise of antimicrobial resistance, the question that remains to be 
answered is:  Can dosing regimens provide maximal clinical efficacy, yet minimize the 
development of antimicrobial resistance?   
A pharmacokinetic / pharmacodynamic approach was utilized to investigate 
oxytetracycline regimens that would impart efficacy while minimizing the potential for 
resistance development due to plasmid transfer.  An in vitro pharmacodynamic model was used 
to quantify the response of a Pasteurella multocida isolate to two oxytetracycline dosing 
regimens.  The PK/PD index most closely related to efficacy was the Cmax:MIC. 
The in vitro pharmacodynamic model was then used to investigate the effects of 
antimicrobial exposure on plasmid transfer.  A mixed population of oxytetracycline-susceptible 
and resistant bacteria was exposed to two dosing regimens and plasmid transfer was quantified.  
When oxytetracycline concentrations exceeded the MIC of the recipient, development of 
resistance was suppressed.  
The same donor and recipient bacteria were used in an in situ swine model to validate the 
in vitro findings.  Following surgical implantation of porous membrane straws containing the 
mixed bacterial population, animal subjects in the treatment groups received one of two 
oxytetracycline treatments.  Oxytetracycline concentrations in the plasma and interstitial fluid 
were quantified.  Plasmid transfer within the implant membranes was quantified and correlated 
 to pharmacokinetic measures in the animal.  Plasmid transfer rates in the implant membranes did 
not correlate to the investigated pharmacokinetic parameters. 
The study methodologies in this dissertation should serve as a foundation for future 
studies in antimicrobial pharmacokinetic/pharmacodynamic research.  The results presented here 
show that the bacterial response to oxytetracycline can be optimized in a concentration 
dependent manner and that antimicrobial resistance development through plasmid transfer can be 
suppressed in vitro when oxytetracycline concentrations exceed the MIC of the recipient 
bacteria.  These results suggest that a proper balance between clinical efficacy and minimizing 
antimicrobial resistance can be achieved for oxytetracycline through appropriate dosing regimens 
and drug formulations. 
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CHAPTER 1 -  Literature Review 
Antimicrobial Pharmacokinetics – Pharmacodynamics 
Pharmacokinetics literally translates to “drug movement”.  It has been defined as the use 
of mathematical models to quantify the time course of drug absorption and disposition in man 
and animals
1
.  Traditionally, this is represented by the ADME scheme:  Absorption, Distribution, 
Metabolism and Excretion
2
.  In lay terms, pharmacokinetics is described as “what the body does 
to the drug”. 
Pharmacodynamics is the discipline which studies “how a drug acts on a living organism, 
including the pharmacologic response and the duration and magnitude of response observed 
relative to the concentration of the drug at an active site in the organism”3.   This is often 
described as “what the drug does to the body”.  However, antimicrobial pharmacodynamics 
represents a unique situation in which the intended drug – receptor interaction is not with the 
host organism, but within the invading microorganism.  In a 2004 review article, Drusano 
describes this as an advantage over traditional pharmacodynamics in that with antimicrobials we 
can directly measure the ability of the anti-infective agent to dock into its „receptor‟ and cause 
the effect for which it was designed by using the Minimum Inhibitory Concentration (MIC) or 
Effective Concentration (EC)
4
.  While these pharmacodynamic measures are relatively easy to 
obtain for a bacterial isolate or population (MIC and EC90), it deserves mention that they are not 
the only pharmacodynamic measures and that other measures of antimicrobial efficacy may be 
appropriate.  However, the MIC is the current accepted standard and will be utilized as the 
antimicrobial pharmacodynamic measure in the research described herein. 
 2 
The combination of antimicrobial pharmacokinetics and pharmacodynamics, or PK/PD, 
is the integration of these two disciplines which describes the bacterial population response to the 
dynamic changes in drug concentrations in a patient over time.  Once the correct PK/PD index 
value has been determined for the specific drug – pathogen combination, dosing regimens can be 
optimized based on the MIC of the isolated pathogen and pharmacokinetics of the individual 
patient.  On a larger scale, the index value can be integrated with procedures such as Monte 
Carlo simulation to set susceptibility breakpoints or assess probability of successful treatment 
outcome based on population pharmacokinetics
5
.   
Development of Pharmacokinetic – Pharmacodynamic Indices 
The field of antimicrobial pharmacokinetics / pharmacodynamics (PK/PD) developed 
shortly after the first antibiotics were discovered.  In the late 1940‟s and early 1950‟s, Dr. Harry 
Eagle performed a series of experiments that would become the earliest PK/PD studies.  His 
group first demonstrated the concentration-independent nature of penicillin.  They noted that 
there was an optimal concentration of penicillin which maximized the kill rate of bacteria; even a 
32,000-fold increase in concentration above the optimal concentration did not accelerate kill 
rate
6
.   In a later study, Dr. Eagle concluded that “the factor that primarily determines its 
[penicillin‟s] therapeutic efficacy is the total time for which the drug remains at effective levels 
at the focus of infection” 7.  The practical application was best summarized:  “Such continuous 
levels could be provided by a continuous drip, or small doses of aqueous sodium penicillin 
repeated at intervals of approximately 2-4 hours”.  Two other noteworthy observations from 
these early experiments were: the persistent bacterial effects on Gram-positive organisms when 
penicillin concentrations declined below the inhibitory concentration and the observation that an 
over-extended dosing interval results in re-growth of the organism.  Taken together, these 
 3 
conclusions show that there is an optimal dosing strategy for penicillin based on a minimum time 
above a concentration at the site of infection to elicit maximal kill.  Unknown to him, Dr. Eagle 
also alluded to what is the basis for this doctoral research, when he stated:  “With the latter group 
of antibiotics [including oxytetracycline] the optimal time-dosage relations remain to be 
determined”. 
In 1974, Klastersky
8
 et al. described the bacterial inhibitory effects of serum and urine 
from antimicrobial-treated patients.  The objective of the study was to correlate individual patient 
antimicrobial concentrations with clinical outcome.  Serum and urine were collected from cancer 
patients with confirmed bacterial infection.  Serum was collected 1 hr post-antimicrobial 
administration (peak) and 1 hr prior to the following administration (trough).  Urine was 
collected on the second day of treatment over the interval between administrations.  For 
septicemia, respiratory and wound infections, the clinical outcome was correlated to the peak 
serum inhibitory titer.  For urinary tract infections, the outcome was correlated to peak urinary 
inhibitory concentrations.  However, the study results are confounded by the use of multiple 
antimicrobials in mono- and combination-therapy.  The study results are also limited because a 
breakpoint of 3µg/mL was used to correlate clinical outcome to inhibitory titer regardless of the 
antimicrobial treatment.  Nevertheless, this study was the first to correlate peak concentrations to 
bacterial effect. 
A hybrid parameter, the area under the time-concentration curve (AUC) is the 
pharmacokinetic measure for total drug exposure.  In that regard, it is actually the oldest index 
although not in a scientific sense.  Prior to the pioneering work of Drs. Eagle, Klastersky and 
others, antimicrobial treatment was administered based on a standard dose.  Individual patient 
and microbe variation were not truly accounted for, but recognized when clinical failures 
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occurred.  The first study to use statistical analysis of antimicrobial pharmacokinetics and 
bacterial pharmacodynamics to determine an optimal PK/PD index and the magnitude of that 
index was conducted by Dr. James Thayer on prison inmates in Georgia
9
. 
The Georgia Prison Study 
Dr. Thayer‟s research (conducted in 1964, published posthumously in 1979) was 
conducted to determine the pharmacokinetic variables of penicillin associated with cure of 
gonococcal urethritis.  Forty-five prison volunteers were experimentally inoculated with 
Neisseria gonorrhoeae.  After developing clinical signs of infection, volunteers were allocated to 
one of six different penicillin regimens and serial blood samples were collected for determination 
of penicillin concentration in each subject.  Clinical cure was defined as negative urethral and 
urine cultures at 72 and 96 hours.  The researchers examined 46 subject and pharmacokinetic 
variables in a stepwise discriminant analysis to determine which contributed to the differences 
between volunteers that were cured and those that were not.  In the final analysis, the authors 
noted the correlation between pharmacokinetic parameters, but the indices including time above 
the MIC best predicted the probability of correctly classifying subjects as treatment cures or 
failures. 
In vivo Models of Antimicrobial Pharmacodynamics 
To determine antimicrobial PK/PD relationships in vivo, either clinical or microbiological 
outcome measures can be utilized.  If a fatal disease model is utilized, animals can be 
administered varying dose regimens to determine which PK/PD index is most predictive of 
survivorship.  For studies with microbiological outcome measures, PK/PD indices are correlated 
to changes in colony forming units to provide the optimal dosing strategy.   
 5 
Virtually any animal model can be utilized for antimicrobial PK/PD research, but the 
neutropenic mouse thigh infection model has emerged as the standard model for this type of 
research.  The murine infection model was first used in the 1960‟s to improve on existing animal 
models of Mycobacterium tuberculosis infection
10
.  The purpose of the original model was to 
describe a non-fatal model for tuberculosis that could be used to provide pathologic description 
of disease progression.  The authors also mentioned the value in assessing chemotherapy, but 
commented that “modification will be necessary before the lesion can be used directly as a 
critical test in chemotherapeutic studies”.  In the early 1980‟s, Gerber, Vastola, Brandel and 
Craig described the procedure for inducing neutropenia, inoculating thigh tissue and quantifying 
bacterial responses in mice
11
.  In that study, the model was used to investigate the development 
of resistance during therapy in vivo without the interaction of a functional immune system.  In 
1988, Craig‟s group published another study that would become the foundation for modern day 
in vivo PK/PD research
12
.  That paper described the comprehensive methods for using a 
neutropenic mouse thigh infection model, a dose fractionation design and statistical regression to 
determine optimal PK/PD indices for 7 different antimicrobial-pathogen combinations.  Since 
this time, the murine thigh infection model has become the standard in vivo dose fractionation 
model for determination of the optimal PK/PD index and magnitude of the index
13, 14
.  In a dose 
fractionation study, one treatment consists of a single administration of the antimicrobial, while 
the subsequent treatments will receive the same total dose divided into 2 or more 
administrations.  This study design therefore limits the interdependence of the primary PK/PD 
indices.  
However, other murine models (inhalational, systemic) can and have been used to derive 
the PK/PD relationships for pneumonia
15,16
, bioterrorism exposures
17
, mycobacterial
18
 and 
 6 
systemic fungal infections
19
.  Other disease models including: pyelonephritis, meningitis, 
osteomyelitis and endocarditis have been reviewed elsewhere
20
.     
Ideally, the PK/PD relationship for any antimicrobial – pathogen combination is tested in 
the target animal.  As described previously, Dr. Thayer used an induced model of gonococcal 
urethritis to derive the PK/PD relationship for penicillin.  In the present day, disease challenge 
models in humans are prohibited due to ethical considerations.  However, the potential to 
determine PK/PD relationships does exist under certain circumstances.  In his 1991 landmark 
study, Schentag collected respiratory and plasma samples from patients with nosocomial lower 
respiratory tract disease to determine the association between pharmacokinetic parameters and 
clinical outcome for ciprofloxacin
21
.  In the final analysis, time above MIC was predictive of 
bacterial eradication with ciprofloxacin.  The methodology does not describe further statistical 
analysis and whether other parameters were useful for prediction.  Subsequent studies have 
demonstrated that fluoroquinolones act in a concentration-dependent manner and thus, the 
optimal PK/PD index is either the Cmax:MIC
22
 or AUC:MIC
23,24
.  
Limitations of in vivo animal models 
One of the potential disadvantages of the neutropenic models (murine or otherwise) is the 
lack of a functional immune system.  For investigations of a clinical nature this represents the 
“worst case scenario”, the immunocompromised patient.  However, for basic PK/PD research 
this is considered an advantage as it will overestimate the magnitude of the PK/PD index 
required for a positive outcome
25
. 
One of the challenges of working with translational animal models in PK/PD research is 
the effects of interspecies differences.  The two potential differences that should be accounted for 
in an animal model are protein binding and intrinsic clearance.  The effects of interspecies 
 7 
clearance differences were demonstrated recently in a study by Deziel et al. in which murine and 
primate models failed to replicate the pharmacodynamic relationship between levofloxacin and 
Bacillus anthracis seen in vitro with humanized drug exposures
26
.  The authors hypothesized that 
the shorter T1/2 in animals (2 hrs vs. 7.5 hrs in humans) resulted in drug concentrations below the 
MIC of the organism for a large portion of the dosing interval.  When animal pharmacokinetics 
were “humanized”, bacterial response was correctly predicted.  As demonstrated by this 
example, if the exact values for these factors are known, dose adjustments (quantity or 
frequency) can be made to approximate desired pharmacokinetics.   
The ability to serially quantify both antimicrobial and pathogen in the same animal is 
desirable; however, for the murine models listed, bacterial quantification requires tissue 
homogenization, obviously a terminal measurement.  A PK/PD methodology that allows 
repeated sampling of the same host for both drug and bacterial quantification would reduce inter-
animal variation and the number of animal subjects necessary for this type of study. 
Interdependence of the primary PK/ PD Indices  
The primary objectives of antimicrobial PK/PD research are to derive the index and 
magnitude of that index that is most predictive of efficacy for a given antimicrobial-pathogen 
combination.  Deriving the index in a clinical study can be difficult due to the variation in 
immune response between individuals.  However, the greatest challenge to this objective lies in 
the interdependence of the three PK/PD indices.  This has been described by others
27,28
, but 
merits further illustration here. 
Three integrated indices have become widely accepted in antimicrobial PK/PD research.  
They are the ratio of the antimicrobial maximal plasma concentration to the minimal inhibitory 
concentration of the pathogen (Cmax:MIC), the area under the plasma time concentration curve 
 8 
to MIC ratio (AUC:MIC), and the time the plasma antimicrobial concentration remains above the 
MIC of the target pathogen (T>MIC)
29
.  Of the three pharmacokinetic components utilized in 
PK/PD indices, only the Cmax is truly independent of the others.  For intravenous dosing, it is 
dependent only on the dose given and the volume of distribution. 
The area under the time-concentration curve (AUC) has both time and concentration 
components.  This is most easily illustrated using the pharmacokinetic equation for AUC 
following a one-compartment intravenous bolus (equation 1), where Cp0 is the extrapolated 
plasma concentration at time zero and T1/2 is the apparent elimination half life for plasma 
concentrations. 
Equation 1: Calculation of AUC 
0.693
T1/2     Cp0
  AUC  
From this equation, it can be seen that AUC is a hybrid parameter with both time and 
concentration components.  It is also obvious that it is a direct relationship where doubling either 
the peak concentration or the half-life will result in a doubling of the AUC. 
Time above MIC is also a hybrid index, but the relationship is even more complex.  If the 
half-life is doubled, then the T>MIC will be twice as long.  If the peak concentration is doubled, 
the T>MIC will increase by one half-life of the antimicrobial.   
The effect of changes in the pharmacodynamic component of the indices, the MIC of the 
pathogen, is quite simply a different permutation of the concentration effects illustrated above.  If 
the pharmacokinetics are constant and the MIC for a pathogen doubles, the Cmax:MIC and 
AUC:MIC will be one-half of their original value.  Given the same scenario, the Time above 
MIC will be reduced by one half-life; therefore, the effect will depend on the pharmacokinetics 
of the specific antimicrobial.  Special emphasis is given to the effect of increasing or decreasing 
 9 
the MIC value by a factor of two because antimicrobial concentrations in microwell 
susceptibility testing are twofold serial dilutions with an accepted error of ± one dilution.  This 
fact is often overlooked in antimicrobial PK/PD research, but it has great impact on the final 
interpretation of the data.   
The most widely used approach to minimize the mathematical interdependence of the 
PK/PD indices is the dose fractionation study.  Dose fractionation studies can be used in vivo or 
in vitro.  If designed properly, the single administration will result in a greater Cmax:MIC ratio, 
while the multiple (fractionated) administration regimen will result in a longer T>MIC.  Given 
this design, the AUC values will be identical for the two regimens.  Thus, AUC:MIC becomes 
the default index to be disproven by showing superiority of one dosing regimen.  If the single 
administration has a more favorable outcome, Cmax:MIC will be most predictive of outcome.  If 
the fractionated dose is superior, then the optimal PK/PD index is T>MIC.  
A second approach to determine the optimal PK/PD index is to collect individual subject 
/ patient pharmacokinetic data and correlate the antimicrobial concentrations to the bacterial 
response in the individual.  The resulting effect-parameter relationship is modeled; generally 
using an inhibitory E-max model.  This model is a sigmoid shaped model with inflection points 
at the concentration where bacterial response is first observed and at the maximally effective 
concentration.  The parameter with the highest correlation value is considered the optimal PK/PD 
parameter.  The biggest disadvantage to this approach is that it requires sufficient 
pharmacokinetic data for each individual subject/patient to determine the exact value of each PK 
parameter.  For experimental challenge models, the pathogen MIC is known but this may prove 
difficult to determine for clinical cases, especially in cases of polymicrobial infection. 
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Additionally, a wide range of pharmacokinetic parameters must be achieved to define the 
optimal magnitude of the parameter.    
In vitro Pharmacodynamic Models 
In an in vitro phamacokinetic model (IVPM), exponential decay of drug concentration is 
simulated by dilution of the antimicrobial-containing media with fresh media.  The two general 
types of in vitro pharmacodynamic models are one-compartment and two-compartment.  In a 
one-compartment model, the antimicrobial is administered directly into the bacterial inoculum.  
In a two compartment model, the bacteria are retained in their respective compartment by a 
membrane or filter, while the antimicrobial moves by gradient diffusion into and out of that 
compartment.  Although this is greatly oversimplified, if the antimicrobial is added directly to 
the compartment containing the bacterial culture, it will be referred to as a one-compartment 
model.  The presence of a retaining membrane will suffice to classify the model as two-
compartment.  Presented below is a description of the historical evolution of these models and a 
critique of their respective usefulness. 
One compartment models 
Early in the history of antimicrobial PK/PD, researchers realized that in vitro scenarios of 
bacterial kill curves had one major limitation, namely the bacteria were exposed to static 
antimicrobial concentrations.  However, in living organisms, the time-concentration profiles of 
antimicrobials are dynamic.  Thus, conclusions based on fixed drug concentrations may not 
correlate with clinical outcome.   
To achieve exponential decay of the antimicrobial in an in vitro setting, the first 
researchers added media to the bacterial culture at selected time points.  To simulate absorption, 
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the added media contained antimicrobial.  To simulate the elimination phase, the added media 
was free of antimicrobial.  The resulting time-concentration profile was not a smooth curve, but 
rather a stepwise rise and decline in antimicrobial concentrations
30, 31
.  Thus, the resulting 
pharmacokinetic simulation only approximated serum antimicrobial concentrations.  A smoother 
curve could be produced by more frequent addition of media; however, this increased the labor 
requirements of the system.   
In 1968, Sanfillipo et al.
32
 compared bacterial responses to short-acting sulfadiazine and 
long-acting sulfamethoxypyrazine.  Although the authors demonstrated a similar bacterial 
inhibition for both treatments compared to the control, the published paper is inadequate to 
support the conclusions.  The greatest limitation to this early model was that the pharmacokinetic 
simulation did not represent the exponential decline of antimicrobial concentrations in vivo.  One 
appraisal of this study cited that because intermittent, not continuous, media flow was used the 
model resulted in a stepwise dilution
33
.  Also, the volume of the bacterial reservoir was not kept 
at a constant volume, so the model did not replicate exponential decay
34
.  In addition, the lack of 
correlation between optical density measurements and viable bacteria counts (colony forming 
unit counts) and the fact that the materials and methods do not describe the method for 
confirmation of antimicrobial concentration within the experimental system makes the 
conclusions difficult to support. 
Improving on this design in 1978 and 1980, two groups of investigators employed the use 
of peristaltic pumps to continually add fresh media to a growing culture of bacteria containing 
antibiotic while also using pumps to maintain constant volume in the central reservoir.  In the 
experimental setup published by Grasso et al. in 1978, IV and parenteral administrations based 
on human pharmacokinetics of three cephalosporins were simulated to study the effects of 
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antimicrobial elimination rate on antibacterial activity
35
.  The addition of a supplementing flask 
allowed for the parenteral simulations.  In this study, the researchers first compared the dilutional 
effects at three rates of media flow (30, 60, 120 min half-life simulations) to a static control 
culture.  They concluded that the bacterial populations were not significantly affected by dilution 
and that results could be compared directly for the three simulated regimens.  Based on viable 
bacterial counts and corresponding drug concentrations, the authors concluded that the potential 
in vivo activity against Klebsiella and E. coli was superior for cefazolin (vs. cephradine and 
cephacetrile) due to its slower elimination and resulting increased time above MIC. 
Murakawa et al. (1980) used a more complex 4 flask model to simulate IV dosing of 
cephalosporins in humans
36
.  In contrast to the conclusions of Grasso et al., these authors stated 
that a mathematical correction factor was necessary to account for bacterial dilution.  The 
difference between the two studies may have been a result of the initial inoculum.  Grasso et al. 
used a starting inoculum of approximately 1 x 10
6
 cells/mL to show that media flow did not 
affect the bacterial population over time.   Murakawa et al. used a 1 x 10
2
 cells/mL starting 
inoculum and compared dilution at 3 flow rates to a static control in deriving their mathematical 
corrections.  However, in their actual IVPM experiments, Murakawa et al. used a starting 
inoculum of approximately 5 x 10
6
 cells/mL.  Because the proposed mathematical corrections 
were only tested at low inoculums, they may not hold true at the bacterial populations used in the 
actual experiments. For any bacterial culture there will be a physical space limitation to growth, 
but nutrient availability may be the primary limitation. 
Schneider et al. (discussed below)
37
 showed that media flow had no effect on the growth 
curves (viable counts and optical density) for Salmonella typhimurium with a starting inoculum 
of 5 x 10
5
 CFU.  To the knowledge of this author, there has not been a publication that compares 
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dilution effects in one-compartment pharmacodynamic models relative to starting inoculum and 
bacterial species growth rates (doubling time). 
One compartment models with filters 
Bacterial dilution and loss in the early one compartmental pharmacodynamic models 
were recognized as problematic in the early days of PK/PD. Mathematical corrections had been 
suggested by Murakawa
38
 and later by White et al.
39
.   Other investigators, however, attempted 
to circumvent the dilution issue by using filters to retain the bacteria within the central reservoir.   
In 1980, Shah used a 3 flask model (central, fresh and waste media) similar to the system 
originally used by Grasso.  However, the waste media was filtered through a porous microglass 
filter (0.5 micron) prior to exiting the central reservoir.  As the author reports, the microglass 
filter was not 100% effective, but reduced bacterial loss to less than 0.14% per minute
40
.  
However, antimicrobial quantification was not performed in this study; conclusions were based 
on expected drug concentrations from the administered dose and pump flow rates. The authors 
failed to cite the potential effects that the filter may have had on simulated drug concentrations.  
For one, the filter could directly bind antibiotic and reduce drug concentrations.  Second, bacteria 
may occlude the filter pores and reduce media outflow, thus prolonging half-life in the system.  
Without measurement of drug concentration either in the central reservoir or on the filter (radio-
labeled drug), the effects of direct binding are unknown.  Reduction in media outflow may have 
been explained by an increase in central reservoir volume or by measurement of total waste 
media.  Neither observation is reported in the publication. 
A slightly more intricate, but improved, system design was described in 1982 by 
Schneider et al.
41
.  The study objective was to measure bacteria responses to three 
cephalosporins.  Target drug concentrations in the system were based on human 
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pharmacokinetics of the respective antibiotics.  Fresh media was pumped into a supplemental 
reservoir prior to entering the central reservoir to simulate the absorption phase of simulated oral 
doses.  Waste media flow was set equal to fresh media flow to maintain constant volume in the 
central reservoir.  The central reservoir was a water jacketed vessel with a fresh media port at the 
top and an outflow port at the bottom.  Above the outflow port was a Millipore GS/HA filter 
(0.45 micron) to retain bacteria in the central reservoir and a stir bar to limit bacterial occlusion 
of the filter.  The antibiotic agent concentrations were quantified by agar well diffusion testing 
and expected concentrations were a near perfect fit to the desired human pharmacokinetic curves.  
Another important aspect of this study pertains to bacterial quantification.  The authors presented 
the direct comparison of turbidimetric (photometric) measurements to viable cell counts 
(plating).  Although not discussed by the authors, it is quite clear that the photometric 
measurements are not sensitive to decreases in viable cells.  This is most likely due to the fact 
that the dead bacteria contribute to turbidity measurements. 
Two compartment models 
Two compartment models began to see widespread use in the early 1980‟s.  Although 
these models still use dilution to simulate the dynamics of drug loss, they incorporate a selective 
barrier to prevent a dilution effect on the bacterial population.  These models differ from the 
model of Schneider et al. only in that the antimicrobial must diffuse across the retaining 
membrane.  In Schneider‟s model, the drug is directly administered into the compartment 
containing the bacterial inoculum (one compartment model).  The first report of a two 
compartment model setup was by Al-Asadi in 1979
42
.  He added connection ports to two test 
tubes and placed a cellulose acetate membrane between them.  One tube held the bacterial 
inoculum, while the antimicrobial (gentamicin) was administered into the other tube.  Diffusion 
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across the membrane resulted in a gradient driven rise in the gentamicin concentrations in the 
bacterial compartment.  Once the desired peak concentration was achieved, media flow into the 
sealed bacterial compartment resulted in back-diffusion of the gentamicin.  The major limitation 
of this model was the imprecision in the control of drug concentrations compared to other 
models.  Two factors contributed to this imprecision:  membrane pores became blocked by 
bacterial debris and membrane composition (type, pore size, and surface area) affected diffusion 
across the membrane. 
Three years later, Craig et al. described an improved two compartment model
43
.  In this 
system, two hemodialyzers were placed in series to increase membrane surface area to 
approximately 1 m
2
.  One side of the membrane was designated the bacterial compartment, while 
the other was designated the drug compartment.  On each side was a closed loop that circulated 
media within the respective compartment.  The drug compartment contained an exchange loop 
through which fresh media was introduced, while at the same rate, drug containing media was 
removed.  In this study, the authors used radio-labeled penicillin to quantify drug concentrations.  
Using radioactivity, they established that equilibrium across the membranes was rapidly 
achieved and that drug binding to the membrane was minimal.   The authors discussed the 
limitation of this method of quantification, namely that radioactivity does not necessarily relate 
to active drug concentration.  The authors also suggested that changing the membrane type 
and/or size would be necessary to alter the absorption characteristics for parenteral dosing 
simulations.    
The model was able to effectively simulate desired drug concentrations.  The primary 
advantage to this model was that the bacterial cells were retained in the system and not diluted 
with the addition of fresh media.  The disadvantages of the system design were: large systems 
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requiring suitable incubators and very large volumes of media to simulate short half-lives (1-2 
hrs), antimicrobial binding must be verified for each membrane/drug combination, directional 
flow of drug containing media could result in an antimicrobial concentration gradient in the 
bacterial compartment, the system is not commercialized - thus difficult to replicate, and the 
potential for biofilm formation on the membrane.    
A variation on the two compartment model by Garrison
44
 was described in 1990.  In this 
model, the second (peripheral) compartment consisted of a T-tube with polycarbonate 
membranes on each end that was submerged in the media of the central compartment.  In this 
publication, the figures showed the lag in concentration between the central and peripheral 
compartments.  This lag is a result of the diffusion necessary for drug movement into the 
peripheral compartment and as such represents a major limitation to all two compartment 
models. 
Capillary models 
In 1981, a publication titled “An artificial capillary in vitro kinetic model of antibiotic 
bactericidal activity” by Zinner, Husson and Klastersky had described what was to become the 
next evolution of PK/PD in vitro models
45
.  The studies subsequently reviewed will attempt to 
highlight the capabilities of the capillary diffusion (hollow fiber) infection models with brief 
discussion of the model limitations. 
The first capillary diffusion model used by Zinner et al. consisted of a reservoir, 
connection tubing (with a single port for sampling and drug injection), a circulating pump and a 
commercially available capillary unit.  The capillary unit was a polycarbonate tube with two 
sampling ports.  Inside the tubes were a bundle of polysulfone capillaries.  The molecular cutoff 
for the capillary pores was 10,000 Daltons.  The bacterial culture could therefore be inoculated 
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and retained in the extracapillary space of the polycarbonate tube. As growth media (and 
antibiotics) flowed through the lumen of the capillaries, the antibiotic and other small molecules 
would diffuse based on the concentration gradients established in the circulating media and 
extracapillary space.  Decreasing antimicrobial concentration was accomplished by removal and 
addition of equal volumes of media from the reservoir at intervals of 30 minutes, 1, 2, 3, 4, 5, 
and 6 hours.  This resulted in a stepwise pharmacokinetic curve similar to the earlier methods of 
Nishida et al. and Leitner et al. Although it had not been done in this study, the authors 
recognized that continuous dilution and removal could be performed in the central reservoir to 
simulate a more realistic pharmacokinetic curve.   
In this experiment, the authors compared bolus to infusion dosing of azlocillin.  Only one 
dose regimen of each administration was evaluated.  Determinations of antibiotic concentration 
in the central and bacterial compartments were by agar well diffusion assay.   
Capillary models, like previous two-compartment models, represented an improvement 
on the one compartment models in that it did not dilute the bacterial culture along with the 
antibiotic.  However, the authors only speculated on the ability to manipulate drug concentration 
in the extracapillary space.  Manipulation of antibiotic concentrations in the bacterial 
compartment was further complicated by the manner in which antibiotic was administered into 
the system.  For bolus dosing, the antibiotic was injected in the circulation loop toward the 
capillary unit.  For infusion dosing, the antibiotic was injected into the circulation loop toward 
the central reservoir.  In addition, the extracapillary space (1.5 mL) in this study was very 
limited.   
In 1985, Blaser et al described the first two compartment in vitro model using 
commercially available capillary units
46
.  The system consisted of a central reservoir which 
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contained culture media (type not given) into which antibiotic was infused to simulate human 
pharmacokinetics of netilmicin and azlocillin.  Connected to the central reservoir was a fresh 
media reservoir, a supplementing reservoir (for infusion of netilmicin due to its longer half-life), 
an elimination reservoir and a circulating loop in which the serially placed capillary units were 
connected.   
The commercial availability of the capillary units (manufactured by Amicon Corporation) 
represented a major improvement in the ease of use and consistency of model use between 
researchers.  In this setup, peristaltic pumps circulated the media in the extracapillary space to 
limit the formation of antibiotic gradients within the individual modules.  This system design 
also represented a potential decrease in the spatial requirements for experiments.  However, this 
presents a disadvantage as well.  The small volumes present in the extra capillary space of the 
modules leads to a larger impact of direct sampling (on the bacterial population).  For example, a 
1 ml sample from the extracapillary space for bacterial and antibiotic quantification in a 350 mL 
reservoir represents a 0.3% decrease in the bacterial population.  The same 1 mL sample from a 
20 mL extracapillary space represents a 5% decrease in the bacterial population.  This limitation 
could be improved by collecting samples from serial modules in a population pharmacokinetic 
manner, but this assumes homogeneity of the capillary units.  This assumption is potentially 
dangerous due to the serial placement of the units.  An antibiotic gradient may be formed in the 
circulating loop as drug diffuses into the extracapillary space of the consecutive units, possibly  
resulting in a time delay of maximal antibiotic concentration in the extracapillary space of the 
downstream serial modules.  Variations of this model have been used to determine optimal 
dosing for therapy of bacterial
47,48
 and viral
49
 infections. 
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Limitations of in vitro models 
Many of the limitations to these models have been discussed above, but for clarity and 
completeness will be summarized here.  Correlation to in vivo results from all in vitro models is 
limited by the lack of immune response in vitro.  The immune component has been successfully 
added to an in vitro pharmacodynamic model in the form of macrophage monolayers and an ex 
vivo implant containing PMN and inflammatory exudate
50
.  However, the lack of a functional 
immune response will likely overestimate PK/PD index values required for efficacy, and thus 
may lend a safety factor to the prediction of in vivo efficacy. 
Although in vitro pharmacodynamic models have been used for over 40 years, the 
methodology for their use has not been standardized, as demonstrated by the number of model 
types currently being used and the publication of two articles to standardize the terminology in 
use by investigators
51, 52
.  Extrapolation between studies is difficult due to the bacterial 
species/strains, initial bacterial inoculum, antimicrobial treatment, and outcome measured.   
These models, like other models, were not intended to provide the final answer to 
questions of therapeutic efficacy.  They should be considered an instrument capable of providing 
intermediary information concerning the interaction of an antimicrobial and a pathogen.  When 
available, model outcomes should be validated through comparison to clinical outcome.  In cases 
where induced disease models are ethically prohibited or naturally occurring disease is rare, 
these models can provide valuable supporting information.  However, they should not be viewed 
as standalone predictors of clinical efficacy. 
Conclusion 
The literature review herein describes the evolution of antimicrobial pharmacokinetic / 
pharmacodynamic theory.  As our understanding of the interactions between antimicrobial and 
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pathogen has grown, the study methodologies and models have concurrently become more 
sophisticated.  However, the full potential of these models in simulating the infectious disease 
process remains to be realized.  Significant obstacles remain in the application of PK/PD model 
outcomes to patient care in the form of questions about the translation of PK/PD indices 
determined in vitro to treat infections in vivo, the utility of the AUC:MIC ratio due to the hybrid 
makeup of the index, and the differences in pathogen MIC values between test systems and 
actual patient disease.  Another key concern is the application of the PK/PD index value 
determined for a single antimicrobial-pathogen combination across the entire antimicrobial group 
and across multiple pathogens.  Additionally, the use of a PK/PD approach to study antimicrobial 
- dosing regimen - pathogen combinations of veterinary importance is absent in the scientific 
literature.  To address these concerns, the research presented here describes a combined in vitro – 
in vivo approach to study the pharmacodynamics of oxytetracycline in terms of both clinical 
efficacy and contribution to antimicrobial resistance development.     
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CHAPTER 2 - Effects of two oxytetracycline dosing regimens on a 
Pasteurella multocida isolate in an in vitro pharmacodynamic 
model 
Introduction 
The objective of this research was to utilize an in vitro pharmacodynamic model (IVPM) 
to compare the responses of a Pasteurella multocida isolate to two oxytetracycline dosing 
regimens.  Our hypothesis was that the shape of the time – concentration curve is therapeutically 
important, thus bacterial responses would be different for the two dosing regimens.  These results 
will enable clinicians to optimize oxytetracycline dosing regimens in the treatment of Pasteurella 
multocida infections by matching the PK/PD index to patient pharmacokinetics and minimum 
inhibitory concentration of the infecting pathogen. 
Pasteurella multocida is a Gram-negative facultative anaerobic bacterium.  In humans, it 
is recognized as a primary agent of infection following animal bites, but has been associated with 
skin, soft tissue, bone and joint infections, as well as, pneumonia, meningitis, endocarditis and 
septicemia
1
.  Although multiple presentations are possible in veterinary species, it is of primary 
importance as a respiratory pathogen of cattle and swine and as the etiologic agent of fowl 
cholera. 
Oxytetracycline is generally considered to be bacteriostatic, inhibiting protein synthesis 
by reversibly binding to the 30s ribosomal subunit.  The bound oxytetracycline molecule 
interferes with the binding of the aminoacyl-transfer RNA at the acceptor site on the mRNA-
ribosome complex and prevents the addition of amino acids to the growing peptide chain
2,3
.
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Oxytetracycline is a broad spectrum antimicrobial agent with activity against Gram-positive and 
Gram-negative, aerobic and anaerobic bacteria.  It is also indicated for treatment of atypical 
infections such as chlamydia, rickettsia, Mycoplasma spp., protozoa and spirochetes.  Veterinary 
product label indications are listed in Table 1.   
The scientific discipline of pharmacokinetics / pharmacodynamics (PK/PD) ultimately 
seeks to correlate drug concentrations with a biologic effect.  In antimicrobial PK/PD, the desired 
effect is death or stasis of the infecting pathogen, which is correlated to measured drug 
concentrations.  The IVPM is a unique tool that has been developed to investigate antimicrobial-
pathogen interactions in a controlled laboratory setting.  This model can be used to elucidate the 
concentration / time-dependent nature of an antimicrobial using a combination of drug exposure 
simulations.  In this study, the IVPM was used to determine the pharmacodynamic relationship 
between oxytetracycline and a Pasteurella multocida field isolate. 
Materials and Methods 
Bacterial Growth Media 
All liquid growth media, including that used in the central and fresh media reservoirs and 
for the growth of the stock cultures, was brain- heart infusion (BHI) broth.  To prepare the broth, 
37 grams of BHI powder
a
 were mixed with 2 L of deionized water.  The mixture was autoclaved 
at 250° F / 18 psi for 45 minutes.  Prepared media was stored at 4° C until IVPM assembly. 
Pasteurella multocida isolate 
Multiple Pasteurella multocida isolates were screened for antimicrobial susceptibility to 
oxytetracycline.  A swine respiratory disease field isolate with a minimum inhibitory 
                                                 
a
 brain-heart infusion media, Sigma Aldrich Chemical Co, St. Louis, MO 
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concentration (MIC) of  µg/mL was used for this study.  The minimum inhibitory concentration 
was determined by use of an extended-range micro-well dilution system
b
. Testing was conducted 
in accordance with guidelines established by the CLSI and determination of susceptibility was 
performed in accordance with CLSI-approved interpretive criteria
4
.   
The selected isolate was streaked on Trypticase Soy Agar (5% sheep blood) plates
c
 and 
incubated overnight at 37
o
C in 5% carbon dioxide.  Isolated colonies were inoculated into brain-
heart infusion broth
d
.  The broth culture was incubated on a rotary shaker
e
 (180 rpm) for 18 
hours at 37
o
C.  Aliquots (1500µL) were stored in 20% glycerin
f
 at -70 C. 
Pasteurella multocida growth curve correlation to optical density 
A growth curve for the bacterial isolate was obtained by inoculating 75 mL of sterile BHI 
broth with 500 µL (approximately 1.25 * 10
9
 CFU) of the frozen isolate. The inoculated broth 
was placed on a shaking incubator
g
 at 37°C and 180 rpm for the duration of the experiment.   
Samples (2 mL) were collected at 0, 2, 4, 8 and 12 hours using sterile technique.  The 
samples were divided after which approximately 1 mL of the sample was placed into a 
spectrophotometer
h
 set to read absorbance at 650 nm.  The spectrophotometer was zeroed using 
blank BHI broth.  The remaining 1 mL was used to perform CFU determination as described 
below. 
                                                 
b
 Sensititer, Trek Diagnostic Systems Inc, Cleveland, Ohio 
c
 Tryptic Soy Agar Plates with 5% sheep blood.  Remel, Inc. Lenexa, KS 
d
 Brain Heart Infusion Broth, Fluka / Sigma Aldrich, Buchs, Switzerland 
e
 Innova4000, New Brunswick Scientific, Edison, NJ 
f
 Sigma Aldrich, St. Louis, MO 
g
 Innova4000, New Brunswick Scientific, Edison, NJ 
h
 Spectronic 601, Milton Roy, Rochester, NY 
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Following incubation at 37°C for 18-24 hours, colonies were counted as described below 
and the average CFU of the duplicates was plotted against the OD reading for that time point 
(Figure 1).   
Macrodilution Susceptibility Testing 
A six hour culture of the P. multocida isolate was grown in brain-heart infusion broth on 
a 180 rpm shaking incubator
i
 at 37°C.  The OD650 was obtained by spectrophotometric
j
 reading.  
The OD reading was converted to a CFU/mL value from the growth curve (equation 6).  The 
bacterial sample was then diluted with blank BHI to obtain a final bacterial inoculant containing 
1x 10
6
 CFU/mL.   
Borosilicate tubes
k
 (12 x 75mm) were pre-filled with blank BHI and freshly prepared 
oxytetracycline stock (10 µg/mL) so that the total volume of each tube was 0.5 mL.  Tube 
dilutions, in duplicate, from 0.5 to 2 µg/mL were prepared in 0.1 µg/mL increments.  A 0.5 mL 
aliquot of the bacterial inoculant was then added to each tube resulting in a starting bacterial 
concentration of 5 x 10
5
 CFU/mL as per CLSI guidelines
5
.  Tubes were loosely covered with 
paraffin and incubated at 37°C for 20 hours. 
The lowest concentration with no visible sign of bacterial growth was determined to be 
the MIC for each duplicate.  The MIC for the isolate was considered to be the average of the two 
replicate measurements. 
 
 
                                                 
i
 Innova4000, New Brunswick Scientific, Edison, NJ 
j
 Spectronic 601, Milton Roy, Rochester, NY 
k
 Fisherbrand disposable glass tubes, Thermo Fisher Scientific, Pittsburgh, PA 
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Experimental stock culture 
Prior to each experimental run, a single aliquot of the seed culture was thawed at room 
temperature and inoculated into approximately 500 mL of brain-heart infusion broth
l
.  The 
inoculated broth was incubated on a rotary shaker
m
 (180 rpm) for 18 hours at 37
o
C.  Fifteen 
milliliters of the culture were collected to sub-inoculate each of the four experimental arms in the 
IVPM setup.  Following inoculation of the central reservoirs, a four hour growth period was 
observed prior to antibiotic treatment.   
Pharmacokinetic targets and dosing regimens 
The targeted pharmacokinetic drug exposure was an area under the time-concentration 
curve (AUC) of 40 µg*hr/mL.  Two dosing regimens were designed a priori using a spreadsheet 
program
n
.  The simulations of the high concentration-short half-life regimen (HC-SHL) and low 
concentration-long half-life regimen (LC-LHL) were based on the published maximal plasma 
concentration (Cmax) and plasma elimination half-life (T1/2) values following intravenous and 
intramuscular dosing, respectively, in swine
6,7
.  These values were then manipulated to fit a one-
compartment pharmacokinetic model following intravenous bolus dosing and minimize the 
interdependence of Cmax and Time>MIC with the same AUC for the two regimens.  To achieve 
the desired exposures in the in vitro pharmacodynamic model (equation 1), the C0 and T1/2 for the 
HC-SHL were set at 11.1 µg/mL and 2.5 hrs, respectively.  The C0 and T1/2 for the LC-LHL were 
set for 2.5 µg/mL and 11.1 hrs, respectively. 
                                                 
l
 Brain Heart Infusion Broth, Fluka / Sigma Aldrich, Buchs, Switzerland 
m
 Innova4000, New Brunswick Scientific, Edison, NJ 
n
 Excel 2003, Microsoft Corp., Redmond, WA 
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Equation 1: Pump calculations in the IVPM 
2
1
693.0
T
Volume
CL
CR
 
Where CL is the pump speed in mL/hr, VolumeCR is the volume of the central reservoir 
in mL and T½ is the desired half-life in hours. 
In vitro Pharmacokinetic Model 
Variations of the model used in this study have been described by others
8,9,10,11
.  The 
model consists of a 500 mL central reservoir (CR)
o
, a 4 L fresh media reservoir
p
, a 4 L waste 
collection reservoir
q
, reservoir caps
r
 and connecting tubing
s
 (Figure 2). All components were 
autoclaved prior to system assembly.  For each experimental run, four of the above described 
systems (two designated oxytetracycline treatments and two associated controls) were 
assembled.  During the experiment, the central reservoir of each system was housed in an 
incubator
t
 at 37 C.  The central reservoir media was constantly stirred by use of a stir rod/plate
u
 
setup. 
Fresh media pump speed was based on equation 1, to achieve a specified half-life.  Waste 
media pump speed was set slightly faster, with the exit port set just above the CR fluid line to 
maintain a constant CR volume.  Dual pump heads were used to control the fresh and waste 
media flow for a given treatment and the associated control arm. To eliminate carryover effects, 
a single CR port was designated for bacterial inoculation and oxytetracycline dosing.  A separate 
                                                 
o
 Bellco Technologies, Vineland, NJ 
p
 Thermo Fisher scientific, Pittsburgh, PA 
q
 Thermo Fisher scientific, Pittsburgh, PA 
r
 Fibercell systems, Fredrick, MD 
s
 Masterflex L/S 13 Platinum cured silicon tubing, Cole Parmer, Vernon Hills, IL 
t
 NuAire IR Autoflow, NuAire, Inc., Plymouth, MN 
u
 IKA Big Squid, Sigma Aldrich, St. Louis, MO 
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port was designated for bacterial and antimicrobial sampling.  Three replicates of each treatment 
(High Concentration / Low Concentration) and the associated control were conducted. 
Antimicrobial treatment 
Oxytetracycline
v
 was used for all experimental replicates with dosing corrections for salt 
and purity.  Drug administration to be simulated was an intravenous bolus; therefore, the 
oxytetracycline powder was dissolved into 15 mL of brain-heart infusion broth immediately prior 
to direct injection into the central reservoir of the IVPM. 
Bacterial quantification 
All bacterial samples were plated immediately after collection.  Bacteria in the central 
reservoir of the IVPM were quantified at inoculation, at oxytetracycline administration, and at 4, 
8, 12, 24, 36, 48, 60, and 72 hours post-oxytetracycline administration.  For each treatment / time 
point sample, 200 µL of sample was pipetted into 1800 µL of sterile phosphate buffered saline 
(PBS) containing 0.015% of a non-ionic detergent
w
 and vortexed for 1-2 seconds.  Two hundred 
microliters (200 µL) of dilution 1 were withdrawn and added to the second tube containing 1800 
µL of PBS/detergent.  This vortex and dilution procedure was repeated for 10 total dilutions.  
Dilutions 3-10 were plated in duplicate; 100 µL of bacterial suspension were pipetted onto blood 
agar plates
x
 and plated using a disposable plating rod
y
.   
Plated samples were incubated at 37 C for 18-24 hours.  Dilution plates with at least 20 
but no more than 200 isolated colonies were used for bacterial quantification according to 
Equation 2. 
                                                 
v
 Oxytetracycline hydrochloride, Sigma-Aldrich, St. Louis, MO  
w
 Tween 80, Sigma Aldrich, St. Louis, MO 
x
 Tryptic Soy Agar Plates with 5% sheep blood.  Remel, Inc. Lenexa, KS 
y
 Lazy L spreader, Sigma Aldrich, St. Louis, MO 
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Equation 2: Colony Forming Unit determination 
10
1
ctorDilutionFa
coloniesisolatedofNumber
mL
CFU  
At each time point, all plates that met the above criteria were counted.  If more than one 
dilution per time point was quantifiable, the average CFU / mL was used for that time point.  The 
lower and upper limits of bacterial quantification were 2*10
5
 and 2*10
13
, respectively. 
Oxytetracycline quantification 
Sample storage 
Samples taken for bacterial quantification were divided.  A 1-2 mL aliquot was 
immediately frozen at -70° C until analysis. 
Sample preparation 
All chemical reagents were analytical grade.  Briefly, 50 µL of internal standard 
(doxycycline
z
 2,000 ng/mL) were added to 50 µL of sample. The analyte and internal standard 
were extracted using 10 µL of concentrated phosphoric acid
aa
 followed by the addition of 150 µL 
of deionized water.  The samples were loaded on HLB solid phase cartridges
bb
 for the extraction 
procedure.  Following the first elution with 5:95 (methanol:water), the columns were washed 
with 500 µL of 5:95 (Methanol:Water) and dried under high vacuum (≈ 20 inches Hg) for 10 
minutes.  Oxytetracycline was recovered from the SPE cartridge using a methanol wash (300 
µL).  A 150 µL sample was then transferred to a HPLC vial and stored at 4°C in the sample 
carousel until analysis. 
                                                 
z
 Doxycycline hyclate, Sigma-Aldrich, St. Louis, MO 
aa
 O-Phosphoric acid, Fisher Scientific, Pittsburgh, PA 
bb
 HLB 10 mg, Waters Corp., Milford, MA 
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Oxytetracycline quantification 
Quantitiation of oxytetracycline was performed using high performance liquid 
chromatography and triple quadrupole mass spectrometry (HPLC/MS/MS).  Chromatographic 
separation was achieved using a gradient elution of 100% (0.2% glacial acetic acid
cc
 in H2O) 
moving to 5% (0.2% glacial acetic acid in H2O):95% (0.2% glacial acetic acid in acetonitrile
dd
) 
on a HPLC system
ee
 with a C18 analytical column
ff
.  Injection volume was 2 µL and flow rate 
was 0.35 mL/min with a total run time of 5 minutes.  Retention times for oxytetracycline and 
doxycycline (IS) were 2.12 and 2.15 minutes, respectively.   
Mass spectrometry utilized an electrospray ionization source
gg
.  The instrument
hh
 was set 
to operate in positive ion mode.  Transitions were monitored at m/z 461 → 426 for 
oxytetracycline and m/z 445 → 321 for doxycycline (internal standard).  The standard curves 
were prepared daily and consisted of 7 non-zero points ranging from 20 to 14,000 ng/mL. Runs 
were accepted if the concentrations were within 15% of the expected value and the fit of the 
standard curve achieved an R
2
 of at least 0.99.  Two quality control samples, low (350 ng/mL) 
and medium (6,000 ng/mL), were run for every 12 samples.  Accuracy and coefficient of 
variation using 2 replicates each of the low and medium quality controls was ±13% and <8%, 
respectively.   
Protein Binding 
Protein binding was determined in brain-heart infusion broth by ultrafiltration / 
centrifugation.  Triplicate 200 µL aliquots of the low (20 ng/mL), medium (500 ng/mL) and high 
                                                 
cc
 Glacial Acetic acid, Fisher Scientific, Pittsburgh, PA 
dd
 Acetonitrile, Fisher Scientific, Pittsburgh, PA 
ee
 Shimadzu LC-20AD, Shimadzu Scientific – North America, Columbia, MO 
ff
 Sunfire C18, Waters Corp., Milford, MA 
gg
 Turbo-Ionspray Atomospheric Pressure Ionization Source, MDS Analytical Technologies, Concord, ON  
hh
 Sciex API 4000, MDS Analytical Technologies, Concord, ON 
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(14000 ng/mL) calibration solutions from the standard curve were pipetted into centrifugal 
filtration vials
ii
.  The vials were centrifuged at 14,000 x g for 30 minutes.  The preparation and 
quantification procedures were as detailed previously with the following exception:  the standard 
curve for protein binding estimate was fit with a quadratic equation (r
2
 = 0.9998) consisting of 6 
points across the range of concentrations.  Accuracy of the standards was within ± 3% of 
expected concentration.  The analytic run consisted of only the standard curve and 9 ultrafiltered 
samples.  Protein binding was calculated using equation 3. 
Equation 3: Calculation of protein binding 
StandardKnown in ion Concentrat
Sample lteredin Ultrafiion Concentrat
 - 1  BindingProtein  
 
  For filtered samples at the low concentration, the centrifuged / filtered sample 
concentrations were above the LOD but below the LLOQ.  For these samples, concentration was 
calculated by dividing the area ratio of the sample by the area ratio of the standard and 
multiplying by the known concentration of the standard.   
Pharmacokinetic analysis 
Time – concentration data were analyzed based on a one compartment intravenous bolus 
model with 1
st
 order elimination.  The analysis was completed with a commercially available 
pharmacokinetic software program
jj
.  Concentration at time 0 is calculated by Equation 4.  The 
elimination rate constant for each experimental unit was determined by regression of all points of 
the time-concentration curve. 
                                                 
ii
 Microcon YM-10m, Millipore Corp., Bedford, MA 
jj
 WinNonlin 5.2, Pharsight Corp., Cary, NC 
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Equation 4: Calculation of C0 
onDistributi of Volume 
 Dose
 C  0  
Where dose is the amount of drug administered in milligrams and volume of distribution 
is the calculated volume of the central compartment (reservoir). 
Statistical Analysis 
In the initial analysis, CFU/mL data were transformed by the natural logarithm prior to 
analysis using a commercial statistical package
kk
.  Data were fit to a repeated measure in time 
model which can be analyzed as a split-plot model when the Huynh-Feldt condition is satisfied
12
.  
Statistical significance was set at p ≤ 0.05. 
Results 
Pasteurella multocida Growth curve 
The data from growth kinetic experiments were best fit to the following exponential 
equation: 
Equation 5: CFU/mL determination from optical density measurement 
CFU/mL = 2E +07 * e
(5.1851)(OD) 
Macrodilution Susceptibility Testing 
The minimum inhibitory concentration in brain-heart infusion broth for the Pasteurella 
multocida isolate used in this study was between 1.1 and 1.2 µg/mL for the two replicates.   
 
                                                 
kk
 SAS 9.3.1, SAS Institute, Cary, NC 
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Protein Binding 
The protein binding in brain-heart infusion broth was non-linear (figure 3).  Measured 
values were corrected according to equation 6. For oxytetracycline concentrations greater than 
700 ng/mL, protein binding was estimated to be < 15% and corrections were not applied. 
Equation 6:  Protein binding correction in brain - heart infusion broth 
% protein bound = -0.066 * Ln (measured OTC concentration) + 0.587 
Pharmacodynamic Determination 
Actual pharmacokinetic parameters were less than target values for both dosing regimens 
(Tables 2 & 3).  Peak drug concentration and AUC values were both numerically higher in the 
HC- SHL treatment, while time above MIC was slightly longer in the LC – LHL treatments.  
Contrast statements (Table 4) did not show statistical differences between the HC – SHL control 
and the LC – LHL control, therefore treatments were compared directly (Figure 4).  When the 
bacterial response in the treated experimental arms was subtracted from the associated control 
arm response, (HC-SHL – HC control vs. LC-LHL – LC control) the comparison of differences 
approached statistical significance (P=0.056) (Figure 5).  However, only the comparison of the 
HC – SHL to the HC – SHL control reached statistical difference (Figure 6). 
Discussion 
This study is the first reported use of an in vitro pharmacodynamic model to study the 
interaction of an antimicrobial and pathogen primarily of veterinary importance.  Although the 
limitations of the model have been discussed previously, several considerations merit mention as 
a guide to future work in this area. 
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To determine the optimal PK/PD parameter in the present study, a variation on the 
traditional dose fractionation study was utilized.  Both dosing regimens were designed to 
simulate an AUC of approximately 40 µg*hr/mL.  Rather than using a fractionated dose to 
minimize the interdependence of time above MIC and maximal concentration, antimicrobial 
exposure simulations of two different half-lives were utilized.  One of the disadvantages to this 
approach in a one-compartment IVPM is the differential rate of bacterial dilution; which may 
confound interpretation of the results.  This effect has been previously shown to be negligible 
and mathematically correctable.  However, these corrections were applied with reference to a 
non-flowing or static system.  Grasso et al.
13
 and Murakawa et al.
14
 had only considered the 
effect of dilution on the bacterial population.  White et al.
15
 considered the effect of media flow 
on growth kinetics, but only corrected for mathematical overestimation of the bacterial 
population as the culture approached the stationary growth phase.  In our study, the comparison 
of HC – SHL control and LC – LHL controls demonstrates that the higher media flow (i.e. 
shorter half-life) resulted in a numerically greater bacterial population.  Utilizing a simultaneous 
control setup for each respective treatment corrects for the possibility of either enhanced or 
impeded growth due to media flow rates and, thus, is superior to the mathematical corrections 
proposed.     
In this study, a period of bacterial growth was observed prior to antimicrobial treatment 
in order to simulate the bacterial population of an established infection.  However, following this 
period, the cultures were in the stationary phase of growth, which poses a limitation on the 
ability to detect bacteriostatic antimicrobial effects.  For pharmacodynamic studies involving 
bacteriostatic agents, it is advisable to initiate treatment during the logarithmic phase of growth. 
 38 
Because the older tetracycline antibiotics were discovered before the advent of modern 
PK/PD investigations, there is very little information in the published literature.  Most has been 
extrapolated from the newer tetracyclines (doxycycline, minocycline and tigecycline).  A mouse 
thigh infection model was used by Van Ogtrop et al.
16
 to demonstrate that both time above MIC 
and AUC:MIC were correlated with bacterial response to tigecycline, with a slightly higher 
correlation for time above MIC.  In contrast, Bowker et al
17
 showed the antibacterial effect of 
minocycline against Staphylococcus aureus was best correlated to AUC/MIC in an in vitro 
pharmacodynamic model simulating human serum concentrations following clinical doses.  
However, these authors also reported that at doses which only achieved bacterial stasis, once 
daily dosing was superior to fractionated doses at the same mg/kg total daily dose.  Thus, at 
lower doses, oxytetracycline acts in a concentration-dependent manner.  This conclusion is in 
contrast to the earlier work of Cunha et al.
18
, who concluded that doxycycline acted in a time-
dependent manner at low multiples of the MIC, and in a dose-dependent manner at 
concentrations 8 -16 x MIC.  The differences could be a result of the study methodology (static 
time-kill for Cunha, in vitro pharmacodynamic model for Bowker), antimicrobial (doxycycline 
for Cunha, minocycline for Bowker) or the pathogen studied (S. aureus ATCC 25923 for Cunha, 
2 clinical strains and 2 laboratory strains [SMH 32985/SMH32034] for Bowker).   
In a recent study using the murine thigh infection model, Crandon et al. demonstrated 
that the free drug AUC:MIC ratio best predicted efficacy against hospital and community 
acquired strains of Staphylococcus aureus for tigecycline
19
.  In this study, time> MIC was least 
predictive of bacterial response for the 7 isolates used.  The authors noted that the poor 
correlation to time was driven by relatively large reductions in the bacterial populations in dosing 
regimens where the time above the MIC was 0% of the dosing interval.  Differences from the 
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results reported here for oxytetracycline and Pasteurella multocida need to be evaluated in light 
of the different antimicrobials and pathogens studied.   
Christianson et al. also showed that AUC:MIC was the most predictive index of bacterial 
response to doxycycline in the murine thigh infection model
20
.  The conclusion as stated by the 
authors of that study was “The 24 hr AUC:MIC is the PK/PD parameter that best predicts the in 
vivo activity of doxycycline against S. pneumoniae”.  This statement emphasizes that PK/PD 
relationships may be drug-pathogen specific.  However, to this author‟s knowledge, no studies 
have previously investigated the pharmacodynamics of oxytetracycline and Pasteurella 
multocida under simulated in vivo exposures.   
The statistical differences between the two dosing regimens reported here suggest that 
oxytetracycline acts in a concentration dependent manner against Pasteurella multocida and that 
the Cmax:MIC is the PK/PD index most closely associated with efficacy.  For the low 
concentration – long half-life exposures, no statistically significant effect on the bacterial 
population was seen compared to respective controls, while the high concentration – short half-
life regimens resulted in a nearly 2 log reduction in the bacterial population.  The comparison of 
the two oxytetracycline dosing regimens shows that a greater reduction in the bacterial 
population can be achieved by increasing the maximal drug concentration.  These results also 
demonstrate that the same AUC applied over different lengths of time may result in different 
bacterial responses.  Further research is required to investigate the implications of the bacterial 
response on clinical outcome of Pasteurella multocida infection, to derive the optimal PK/PD 
index, and the magnitude of that index that optimizes treatment success. 
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 Figures and Tables 
Figure 1: Pasteurella multocida growth curve 
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Growth curve was determined in brain-heart infusion broth.  Optical density is absorbance read 
at 650 nm.  This growth curve was used to provide proper inoculum size in macrobroth dilution 
determination of MIC. 
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Figure 2: In vitro pharmacodynamic model setup 
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Table 1: Veterinary Label Indications for oxytetracycline 
Species / Class Route of administration Disease Indication 
Finfish Immersion  Fluorescent Marker 
Chickens
‡
 Water additive  Infectious synovitis caused by Mycoplasma synoviae 
 Chronic respiratory disease caused by Mycoplasma gallisepticum and 
Escherichia coli 
 Fowl cholera caused by Pasteurella multocida 
Turkeys‡ Water additive  Hexamitiasis caused by Hexamita meleagridis 
 Infectious synovitis caused by Mycoplasma synoviae 
 Growing turkeys- complicating bacterial organisms associated with 
bluecomb 
Swine‡ Water additive  Bacterial enteritis caused by Escherichia coli and Salmonella cholerasuis 
 Bacterial pneumonia caused by Pasteurella multocida 
 For breeding swine: Leptospirosis caused by Leptospira pomona 
Calves, Beef cattle 
and Non-lactating 
Dairy cattle‡ 
Water additive  Bacterial enteritis caused by Escherichia coli 
 Bacterial pneumonia (shipping fever complex) caused by Pasteurella 
multocida 
Sheep‡ Water additive  Bacterial enteritis caused by Escherichia coli 
 Bacterial pneumonia (shipping fever complex) caused by Pasteurella 
multocida 
                                                 
 Oxymarine product label (Alpharma)  Compendium of Veterinary Products 10
th
 ed.  North American 
Compendiums. 2007.   
‡
 Oxy-mycin 10 product label (AgriPharm)  Compendium of Veterinary Products 10
th
 ed.  North American 
Compendiums. 2007.   
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Species / Class Route of administration Disease Indication 
Beef cattle,  
Beef calves,  
Non-lactating dairy 
cattle 
and Dairy calves
§
 
Intravenous 
Intramuscular 
Subcutaneous 
 Bacterial pneumonia and shipping fever caused by Pasteurella sp. and 
Hemophilus sp. 
 Infectious bovine keratoconjunctivitis caused by Moraxella bovis 
 Bacterial enteritis caused by Escherichia coli 
 Necrotic pododermatitis caused by Fusobacterium necrophorum 
 Calf diphtheria caused by Fusobacterium necrophorum 
 Wooden tongue caused by Actinobacillus lignieresii 
 Leptospirosis caused by Leptospira pomona 
 Wound infections and acute metritis caused by infection of 
oxytetracycline-susceptible strains of staphylococcus and streptococcus 
Swine
§
 Intramuscular  Bacterial enteritis caused by Escherichia coli 
 Bacterial pneumonia caused by Pasteurella multocida 
 Leptospirosis caused by Leptospira Pomona 
 In sows, as an aid in the control of enteritis in suckling pigs caused by 
Escherichia coli 
 
Cattle◊ Medicated Feed  Bacterial enteritis caused by Escherichia coli 
 Bacterial pneumonia caused by Pasteurella multocida 
 
Catfish◊ Medicated Feed  Control of bacterial hemorrhagic septicemia 
 Control of pseudomonas disease 
 
                                                 
§
 Oxytetracycline 200 injection product label  (Aspen)  Compendium of Veterinary Products 10
th
 ed.  North 
American Compendiums. 2007.   
§
 Oxytetracycline 200 injection product label  (Aspen)  Compendium of Veterinary Products 10
th
 ed.  North 
American Compendiums. 2007.   
◊ Terramycin Type A Medicated Article (Phibro animal health) NADA # 008-804. 
www.accessdata.fda.gov 
◊ Terramycin Type A Medicated Article (Phibro animal health) NADA # 008-804. 
www.accessdata.fda.gov 
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Figure 3:  Protein binding in brain – heart infusion broth 
 
 
Determination of protein binding is detailed in the text.  Plot of oxytetracycline concentration vs. 
percent protein binding yielded a logarithmic function.  Three replicates at three concentrations 
were ultrafiltered to produce the plotted values. 
 
 45 
 
 
Table 2: Targeted pharmacokinetics in the in vitro Pharmacodynamic Model 
Parameter HC-SHL LC-LHL 
Cmax 11.08 µg/mL 2.5 µg/mL 
T 1/2 2.5 hr 11.08 hr 
T>MIC 8.75 hr 13.25 hr 
AUC 39.88 hr*µg/mL 39.88 hr*µg/mL 
 
 
Table 3: Achieved pharmacokinetics in the in vitro Pharmacodynamic Model 
Dosing Regimen fAUC : MIC fCmax : MIC fTime > MIC 
HC 37.70 11.32 8.08 
HC 35.20 8.62 8.8 
HC 32.90 8.19 8.45 
HC Average ± SD 35.27 ± 2.40 9.38 ± 1.70 8.44 ± 0.36 
LC 30.02 1.88 10.08 
LC 29.27 1.78 9.48 
LC 31.67 2.00 10.98 
LC Average ± SD 30.32 ± 1.23 1.89 ± 0.11 10.18 ± 0.75 
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Table 4: Statistical comparisons of the bacterial responses for the following in vitro 
pharmacodynamic model dosing regimens 
Contrast Statement P- value 
HC-SHL control v. LC-LHL control 0.0803 
HC-SHL v. LC-LHL <0.0001 
HC-SHL - HC-SHL control v. LC-LHL - LC-LHL control <0.0001 
HC-SHL v. HC-SHL control 0.0016 
LC-LHL v. LC-LHL control 0.162 
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Figure 4: Mean Pasteurella multocida (± standard error) concentrations in Low 
Concentration-Long half-life control and High Concentration-Short half-life control 
(p=0.227) 
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Figure 5: Mean Pasteurella multocida (± standard error) concentrations expressed as the 
differences in High Concentration-Short half-life minus High Concentration-Short half-life 
control and Low Concentration-Long half-life minus Low Concentration-Long half-life 
control (p=0.056) 
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Figure 6: Mean Pasteurella multocida (± standard error) concentrations for High 
Concentration-Short Half Life and High Concentration- Short Half Life control (p=0.0016) 
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CHAPTER 3 - Effects of two oxytetracycline dosing regimens on 
horizontal transfer of antimicrobial resistance plasmids in an in 
vitro pharmacodynamic model 
Special acknowledgement goes to Greg Peterson, collaborator on the 
microbiological aspects of Chapters 3 & 4. 
Introduction 
The remarkable adaptive abilities of bacteria have lead to the phenomenon of 
antimicrobial resistance.  Just 30 years ago, we were “closing the book on infectious diseases”1.  
Today, we face a global pandemic of re-emerging infectious diseases brought around, in part, by 
antimicrobial resistance.  Three key factors have been recognized in the emergence of bacterial 
resistance:  mutation, bacterial genetic exchange, and selective pressure in health care and 
community settings
2
.  Of these factors, the primary focus has been investigating methods to 
decrease the selective pressure within health care and the community by focusing on prudent 
drug use
3,4,5
.  The importance of prudent antimicrobial use has also been recognized in veterinary 
medicine as evidenced by the American Veterinary Medical Association‟s policy statement on 
judicious therapeutic use of antimicrobials
6
.  For veterinarians, the prevention of antimicrobial 
resistance has important implications in our obligations to both public health and the successful 
treatment of our patients.  This is particularly true in production animal medicine where these 
goals are often depicted as contradictory in the public debate. 
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 The roles of mutation and dosing strategies to minimize resistance development have 
been studied extensively, giving rise to theories such as the much-debated Mutant Prevention 
Concentration
7,8,9,10
.  There is also a plethora of literature in regard to the mechanisms of 
bacterial gene exchange
11
; however, relatively little has been published regarding the influence 
of drug exposure on the rates of conjugative transfer
12
. 
The issue of antimicrobial resistance has resulted in a paradigm shift with regard to 
investigation of antimicrobial therapeutics.  Since the late 1990‟s, researchers have sought dosing 
regimens that impart not only clinical efficacy, but also minimize the development of 
antimicrobial resistance.  Consistent with these goals, the objective of this research was to 
describe the relationship between drug exposure and rate of plasmid transfer in an in vitro 
pharmacodynamic model.  Our hypothesis was that oxytetracycline exposure has an impact on 
the rate of plasmid transfer between bacterial species.  Results of this study provide information 
for the development of oxytetracycline dosing regimens that minimize the horizontal transfer of 
antimicrobial resistance genes. 
Materials and Methods 
Bacterial Species/Strains 
 Salmonella enterica subspecies enterica serovar Typhimurium 5678, containing a 
plasmid approximately 100kB in size with resistance markers for chloramphenicol, streptomycin, 
sulfisoxazole, trimethoprim-sulfamethoxazole, tetracycline and beta-lactams, was used as the 
resistant plasmid donor strain.  Both donor and the plasmid recipient bacteria, E. coli C600N, 
had been utilized previously for plasmid transfer experiments
13
.  Aliquots of the stock bacteria 
were stored at -80º C. 
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Determination of Minimum Inhibitory Concentration (MIC) 
The minimal inhibitory concentration for each of the study bacteria was determined by 
modification of CLSI recommended procedures
14
.  Ten microliters of a 0.5 McFarland bacterial 
suspension were pipetted into 11 mL of Luria-Bertani (LB) broth
A
.  Aliquots of the bacterial 
suspension (100 µL) were added to the wells of a 96 well plate
B
.  One hundred microliters of 
oxytetracycline solution had been previously added to the wells, so that the final concentrations 
tested were: 0, 1, 5, 25, 50, 75, 100, 125, 150, 175, 200, 250, 500, 750, and 1000 ng/mL.  Testing 
was done in duplicate for the donor and recipient strains.    
The plates were placed in an incubated spectrophotometer
C
 set to read absorbance at 600 
nm with readings taken hourly.  The inhibitory concentration was determined to be the lowest 
concentration at which optical density readings were reduced.   
Experimental Stock Culture 
 Single frozen aliquots of the Salmonella and E. coli were thawed at room temperature.  
The bacteria were streaked for isolation on LB agar plates
D
.  A single colony of each bacteria 
was transferred to separate flasks containing 10 mL of sterile brain-heart infusion broth
E
 and 
incubated overnight at 37º C on a rotary shaker
F
.  The entire 10 mL of the overnight cultures 
were transferred into separate flasks containing 90 mL of sterile brain-heart infusion broth.  Both 
bacterial cultures were grown to logarithmic phase growth (ODA600 = 0.6)
G
.  Once the desired 
                                                 
A
 BD, Franklin Lakes, NJ 
B
 Corning Costar 96 well plates, Sigma Aldrich, St. Louis, MO 
C
 SpectraMax 190, Molecular Devices, Sunnyvale, CA   
D
 BD, Franklin Lakes, NJ 
E
 Sigma Aldrich, St. Louis, MO 
F
 Gallenkamp orbital incubator, Sanyo-Gallenkamp, Loughborough, Liecestershire, UK 
G
 Spectronic 20D+, Thermo Scientific Corp., Waltham, MA 
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optical densities were reached, the Salmonella and E. coli were transferred to syringes
H
 in a 1:5 
volumetric ratio.  Five mL of the bacterial mixture was inoculated into each central reservoir of 
the in vitro pharmacodynamic model systems.  A one hour growth interval was observed in the 
systems prior to oxytetracycline administration. 
In vitro Pharmacokinetic Model (IVPM)  
The IVPM has been described in detail in Chapter 2.  All bacterial growth media, system 
setup, calculations and components were the same as previously described.  Pump speed was set 
accordingly to achieve the desired half-lives outlined in Table 5.  The two dosing regimens were 
modifications of intravenous
15
 and intramuscular
16
 dosing of oxytetracycline in swine.  The 
intravenous dose was designed so that initial peak concentrations were above 1000 ng/mL and 
time within the 150-1000 ng/mL range would be minimized.  The intramuscular simulation was 
designed so that drug concentrations would remain within the 150-1000 ng/mL range for a 
comparatively longer period of time.  Each of the three (3) replicate runs included: High 
Concentration Short Half-Life, High Concentration Short Half-Life control, Low Concentration 
Long Half-Life, and Low Concentration Long Half-Life control.   
Antimicrobial Treatment 
Analytical grade oxytetracycline as the hydrochloride salt was diluted in fresh brain-heart 
infusion broth prior to dosing in the IVPM.  Corrections for salt and purity were made to achieve 
oxytetracycline concentrations outlined in Table 5. 
 
 
                                                 
H
 Monoject 12 mL regular luer syringe, Kendall, Mansfield, MA  
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Bacterial Quantification & Determination of plasmid transfer 
Samples were collected from the central reservoir of the IVPM at 12, 24 and 36 hours 
after oxytetracycline administration.  The 1-1.5 mL sample was centrifuged at 5,000 x g for 10 
minutes.  The supernatant was pipetted into cryovials and stored at -70º C for oxytetracycline 
quantification as described below.  The bacterial pellet was resuspended with 122.5 µL of 
phosphate buffered saline (PBS) by brief vortexing.  Twenty-two and one-half microliters (22.5 
µL) of the suspension was serially diluted in 202.5 µL of sterile PBS to the -8
th
 dilution.  
Transconjugant bacteria were quantified by duplicate plating of 50 µL of the -1, -4, -6 and -8 
dilutions on Hektoen enteric agar containing 50 µg/mL of ampicillin and 12 µg/mL nalidixic 
acid.  Salmonella (the donor) were quantified by plating 50 µL of the -4, -6 and -8 dilutions on 
Hektoen enteric agar containing 50 µg/mL of ampicillin.  E. coli (the recipient) were quantified 
by plating 50 µL of the -4, -6 and -8 dilutions on Hektoen enteric agar containing 12 µg/mL 
nalidixic acid.  Colony-Forming unit counts were determined as by Equation 1. 
 
Equation 1: Colony forming unit calculation for transconjugant, donor and recipient 
bacteria 
 
FactorDilution 
1
 * 20 * colonies ofNumber   / mLCFU  
 
Equation 2:  Calculation of Transconjugant (TC) ratio 
(CFU/mL) BacteriaDonor 
(CFU/mL)gant Transconju
  ratio TC  
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Oxytetracycline quantification 
Samples were prepared by the solid phase extraction method, and analyzed by a 
LC/MS/MS method described in Chapter 2 for oxytetracycline in brain-heart infusion broth.  The 
standard curve consisted of 6 non-zero points ranging from 20 ng/mL (LLOQ) to 14,000 ng/mL.  
The run was accepted if the concentrations of the standards were within 15% of the expected 
concentration and the fit of the curve was at least 0.99.  Two low (350 ng/mL) and two medium 
(6000 ng/mL) quality controls were run; one low QC was more than 20% different from the 
expected value.  The accuracy and coefficient of variation of the remaining QC samples were ± 
19% and ± 17%, respectively. 
Corrections for protein binding 
Procedures and analytical methods for determination of protein binding in brain-heart 
infusion broth are described in Chapter 2.  Protein binding in brain-heart infusion broth was non-
linear between 20 and 14,000 ng/mL.  For concentrations > 700 ng/mL, protein binding was 
estimated at less than 15% and was not corrected.  For the Low concentration dosing regimen, 
one concentration measurement was above 700 ng/mL (751), but for consistency, all data for this 
regimen were corrected for protein binding according to equation 4 (Chapter 2).  For the High 
concentration dosing regimens, the 12 hour samples were above 700 ng/mL and the 36 hour 
samples were below the LLOQ of the assay, so no corrections were applied.  The 24 hour sample 
for all high concentration replicates was corrected for protein binding.   
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Statistical Analysis 
Statistical analyses were performed using a commercial software package
I
.  
Transconjugant (TC) ratios were logarithmically (base 10) transformed prior to statistical 
analysis.  The lower limit for the calculation of the transconjugant ratio is detailed in equations 
3-5.  The TC ratios were analyzed by timepoint using one-way ANOVA with treatment as the 
independent variable.  Statistical significance was set a priori at the p=0.05 level. 
Equation 3: Upper limit of quantification for donor 
CFU/mL 10^10x  4 
 plated) dilution(highest  10^8 * plated) (volume 20 * counted) colonies (max. 200  ULOQ
 
Equation 4: Lower limit of quantification for transconjugants 
 
Equation 5:  Lower Limit for TC ratio 
10^-10x  5  
10^10x  4
20
 
Donor ULOQ
 LLOQTC
  ratio TC for thelimit Lowest  
Results 
During determination of the MIC values, growth reductions were generally seen 
following 8-12 hours of incubation.  The oxytetracycline MIC for the E. coli (recipient bacteria) 
was 125 ng/mL.  The MIC for the Salmonella (donor bacteria) was 60,000 ng/mL. 
Four of the time points in the treated replicates had transconjugant ratios of zero (no 
transconjugant colonies).  Three of these time points were at 12 hours (2 LC-LHL and 1 HC-
SHL), while the fourth time point was a LC-LHL replicate at 36 hours (Table 5).  The mean 
transconjugant ratios for the HC-SHL control and LC-LHL controls were not significantly 
                                                 
I
 SAS 9.3.1, SAS Institute, Cary, NC 
CFU/mL 20 plated)  for volumet (adjustmen 20 * (colony) 1  LLOQ
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different at any of the three timepoints.  At 12 hours, the transconjugant ratios for the High 
Concentration and Low Concentration treatments were statistically less than the respective 
controls (p=0.01 for both contrasts).  At the 24 and 36 hour timepoints, the High Concentration 
treatment was not significantly different from its respective control (p=0.24 and 0.98, 
respectively), while the comparison of the Low Concentration treatment to its control 
approached significance at both timepoints (p=0.057 and 0.062, respectively).  The transfer rate 
comparison of the High concentration to Low concentration treatment was not significantly 
different at 12, 24 or 36 hours (p= 0.65, 0.70, and 0.13), respectively.  Results are presented 
graphically in figures 10, 11, 12.   
Discussion  
There is a growing body of in vitro evidence suggesting that the development of 
antimicrobial resistance within a population of bacteria can be suppressed by extrapolating the  
pharmacokinetic/pharmacodynamic indices associated with clinical efficacy
17,18,19
.  The primary 
focus of these studies have been on the outgrowth of resistant bacteria: either originating from 
genetic mutation or pre-existing within the population.  In contrast, the study reported here 
focuses on the development of antimicrobial resistance due to emergence of resistant organisms 
following the acquisition of a horizontally transferred plasmid.    The importance of this 
mechanism of resistance development in bacterial populations has been discussed 
previously
20,21,22
. 
The in vitro pharmacodynamic model is an ideal laboratory tool to study the most basic 
interactions between antimicrobials and pathogens.  A limitation to the one-compartment IVPM 
utilized here is the dilution effect on the bacteria caused by inflow of fresh media to the central 
reservoir.  Because the transconjugant ratios of the HC-SHL and LC-LHL controls were not 
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significantly different at any time during the experiments, the effect of dilution rate was 
considered negligible.  Another limitation of the IVPM under the described conditions is the 
favorable advantage given to the bacterial population.  The type of growth media, the constant 
inflow of nutrients and removal of waste products, inoculum size, timing of treatment and 
temperature at which the experiments are conducted, and lack of a functional immune system 
give every conceivable advantage to the bacterial pathogen.  For the present study, conjugative 
events may also be favored (compared to filter mating studies) given the absolute number of 
donor and recipient bacteria present in the culture system, and the constant stirring present in the 
IVPM.  Results of the present study should be interpreted as the “best case” scenario for plasmid 
transfer given the in vitro conditions of the experiment.   
The transfer rates in the present study are in agreement with the conjugative rates found 
by Showsh and Andrews
23
.  Using two Bacillus strains, the authors reported filter mating transfer 
rates ranging from 1 x 10
-1
 to <1 x 10
-8
, when the donor was pre-grown in the presence of 
tetracycline (10 µg/mL).  These authors also demonstrated that at low tetracycline concentrations 
(during mating) the conjugative frequency was enhanced.  Although transfer rates noted in the 
previous work were achievable in our research, the conclusions are quite different with regard to 
the effects of drug exposure on plasmid transfer.  The conclusions from Showsh and Andrews 
suggest that tetracycline exposure during either the pre-growth or mating period increases 
conjugation frequency, while in the present study oxytetracycline exposure suppressed transfer 
rates.  The previous authors hypothesized that the enhanced conjugation was a direct effect on 
the donor strain, not antibiosis of the recipients.  
In a paper by Torres et al.
24
, conjugal transfer rates were also shown to be enhanced in 
the presence of tetracycline for E. faecalis.  Filter matings were performed at static 
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concentrations (10 µg/mL) of tetracycline, as compared to the dynamic pharmacokinetics in 
liquid culture described here.  Due to the static drug exposures in the Showsh et al. and Torres et 
al. and the dynamic drug exposures in the present study it is difficult to make direct comparisons 
of the results.  In fact, results in Appendix A of this dissertation would suggest that the static 
exposures in the studies by Showsh et al. and Torres et al. were not true static exposures due to 
oxytetracycline degradation.  Failure to account for the actual drug exposure limits the 
conclusions that can be drawn from these studies.  To the author‟s knowledge, there are no 
studies investigating the effects of oxytetracycline on conjugative plasmid transfer with 
simulated in vivo antimicrobial exposures.   
Previous static concentration experiments
25
 with the donor and recipient bacteria used 
here had shown that plasmid transfer was bimodal, with higher rates of transfer at concentrations 
less than the growth inhibitory concentration (125 ng/mL) and concentrations between 150-1000 
ng/mL.  The results presented here show that conjugation was suppressed when antimicrobial 
concentrations exceeded the inhibitory concentration of the recipient strain.  In contrast to 
previous work, at no time points did oxytetracycline exposure enhance the conjugation rates.  
The discrepancy may be a result of differences in either the laboratory conditions (filter vs. liquid 
culture) or the drug exposure profiles (static vs. dynamic).   
The transconjugant ratio was calculated according to the method of Hirt et al.
26
 using 
Equation 8 above.  Because the transconjugant ratio is a hybrid of two individual measures, both 
require examination to make inferences about the ratio.  One limitation of this study was that the 
plating procedures were not normalized for sample volume.  However, the Salmonella 
population in the control replicates was numerically greater than in the treated replicates.  The 
potential impact on the transconjugant ratio due to changes in the Salmonella population alone is 
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approximately 0.5 log decrease for the oxytetracycline exposed populations.  The decrease in the 
transconjugant ratio seen here was driven by relative fewer transconjugants formed in the treated 
populations, not by a comparative increase in the number of donor organisms. 
The results presented here show suppression of conjugative transfer in the 
oxytetracycline treated systems at 12 hours when compared to the respective controls. This 
difference is not present at 24 and 36 hours because the transconjugant ratios in the controls have 
decreased to the level of the treated systems.  Two observations merit discussion:  the peak rate 
of plasmid transfer occured early in the time course of the study and the development of 
transconjugant bacteria was suppressed by exposure to oxytetracycline.  Both observations can 
be related to effects of bacterial growth.  If conjugation is a function of bacterial growth, then a 
change in bacterial growth due to either the inherent growth properties of the bacterial population 
(stationary / death phase) or the induction of bacterial stasis due to the presence of an 
antimicrobial, would suppress horizontal gene transfer as was seen in the present study for the 
treated bacterial populations.  Although not statistically significant, the suppression of the 
transconjugant ratio in the low concentration regimens was numerically present at all time points.  
This suppression was not statistically different at 24 hours nor numerically present at 36 hours in 
the high concentration regimen, when corresponding oxytetracycline concentrations were below 
the MIC of the recipient bacteria (Figures 10-12).   
It is inappropriate to use low power estimates to infer differences where statistical 
significance was not obtained.  However, numerical differences within relatively low powered 
studies are legitimately used as an incentive for further studies with greater power.  Using the 
difference in means and standard deviations in the low concentration regimens at 24 and 36 
hours, 3 replicates of each treatment gives a study power of approximately 0.57 or a probability 
 63 
of > 0.4 for a false negative result.  These findings provide preliminary insight into the 
relationship between drug exposure and the development of antimicrobial resistance due to 
horizontal gene transfer.  Future studies are needed to investigate other antimicrobial-pathogen 
combinations and to validate these findings in vivo. 
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Figures and Tables 
Table 5: Transconjugant ratio (log10) and oxytetracycline concentration by timepoint.   
Time Treatment Log TC ratio ± 
SD 
free Oxytetracycline concentration ±  SD 
(ng/mL) 
12 hour LC – LHLJ -8.80 ± 0.86a  514.16 ± 126.77 
LC – LHL control -6.19 ± 1.21b -- 
HC – SHLK -8.40 ± 0.81a 636.56 ± 30.34 
HC – SHL control -5.64 ± 1.31b -- 
24 hour LC - LHL -7.83 ± 0.64
 a
 383.04 ± 86.05 
LC – LHL control -6.90 ± 0.58 a -- 
HC - SHL -8.00 ± 0.55
 a
 62.83 ± 16.76 
HC – SHL control -7.46 ± 0.03 a -- 
36 hour 
 
 
 
LC - LHL
L
 -8.66 ± 0.65
 a
 222.51 ± 41.13 
LC – LHL control -7.74 ± 0.60 a -- 
HC - SHL -7.95 ± 0.34
 a
 Below LLOQ 
HC – SHL control -7.96 ± 0.43 a -- 
                                                 
J
 Ratio set equal to -9.3 (LLOQ) in two of three time points 
K
 Ratio set equal to -9.3 (LLOQ) in one of three time points 
L
  Ratio set equal to -9.3 (LLOQ) in one of three time points 
Transconjugant ratios with different superscripts at each time point differed significantly (p=0.05).   
**-- no oxytetracycline treatment. 
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Figure 7:  Transconjugant ratio (log10) by treatment at the 12 hour time point 
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Replicates with * are significantly different from respective controls 
** For the LC-LHL treatment, two replicates had no transconjugant colonies and were set at the 
lowest possible TC ratio (-9.3) 
** For the HC-SHL treatment, one replicate had no transconjugant colonies and was set at the 
lowest possible TC ratio (-9.3) 
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Figure 8: Transconjugant ratio (log10) by treatment at the 24 hour time point 
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Figure 9: Transconjugant ratio (log10) by treatment at the 36 hour time point 
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** For the LC-LHL treatment, one replicate had no transconjugant colonies and was set at the 
lowest possible TC ratio (-9.3) 
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CHAPTER 4 - Effects of two oxytetracycline dosing regimens on 
horizontal transfer of antimicrobial resistance plasmids in situ. 
Introduction 
The objective of this research was to compare the effects of two different oxytetracycline 
dosing regimens on the rate of horizontal gene transmission between Salmonella enterica and E. 
coli in an in situ swine model using bacterial cultures contained within semi-permeable 
membranes.  The research hypothesis was that plasmid transfer can be suppressed by proper 
oxytetracycline dosing.  These results serve to increase our understanding of antimicrobial 
resistance development through horizontal gene transfer, the role of antibiotic exposure on the 
suppression / enhancement of these transfer rates in vivo, and the application of a novel swine 
model for in situ evaluation of the effect of antimicrobials on bacterial gene transfer rates. 
Study Overview 
Nine pigs were anesthetized for surgical implantation of jugular catheters, interstitial 
fluid probes and implant membranes containing a mixed bacterial population.  Following a brief 
recovery period, animals were either administered IV or IM oxytetracycline or served as 
untreated controls based on prior group assignment.  Plasma and interstitial fluid samples were 
collected over a 12 hour period, at which time the animals were euthanized.  The implant 
membranes were then dissected from the subcutaneous space with quantification of the bacterial 
contents.  Oxytetracycline concentrations were quantified using a LC/MS/MS method and 
correlated to bacterial transconjugant ratios. 
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Materials and Methods  
Study Animals 
Nine (9) crossbred pigs were sourced from a commercial swine operation in north central 
Kansas.  All subjects were determined to be healthy by physical examination upon arrival.  Prior 
to initiation of the study, an 8 day acclimation period was observed.  Animals were fed a non-
medicated commercial swine ration and monitored daily for clinical signs of disease.  The study 
protocol was approved by the Institutional Animal Care and Use Committee at Kansas State 
University.  
Randomization 
The study was a randomized complete block design.  Each block contained one of each of 
the following 3 treatments: intravenous oxytetracycline, intramuscular oxytetracycline, or 
untreated control.  Animals were assigned to blocks by use of random numbers, and then 
randomized within blocks a second time to determine surgical order. 
Bacterial strains 
Salmonella enterica subspecies enterica serovar Typhimurium 5678, containing a 
plasmid approximately 100kB in size with resistance markers for chloramphenicol, streptomycin, 
sulfisoxazole, trimethoprim-sulfamethoxazole, tetracycline and beta-lactams, was used as the 
resistant plasmid donor strain.  Both donor and the recipient bacteria, E. coli C600N, had been 
utilized previously for plasmid transfer experiments
1
.  Minimum inhibitory oxytetracycline 
concentrations for these strains had been previously determined to be 125 ng/mL for the E. coli 
isolate and 60,000 ng/mL for the Salmonella isolate by the methods described in Chapter 3. 
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Bacterial implant membranes 
Stock cultures were started from single frozen aliquots of both the Salmonella and E. coli 
isolates by thawing at room temperature.  The bacteria were streaked for isolation on LB agar 
plates
A
.  A single colony of each bacteria was transferred to separate flasks containing 10 mL of 
sterile brain-heart infusion broth
B
 and incubated overnight at 37º C on a rotary shaker
C
.  The 
entire 10 mL of the overnight cultures were transferred into separate flasks containing 90 mL of 
sterile brain-heart infusion broth.  Both bacterial cultures were grown to logarithmic phase 
growth (ODA600 = 0.6)
D
.   The logarithmic cultures were mixed in a 1:5 (donor: recipient ratio) 
which was used to fill each full length implant membrane
E
 (approximately 250 µL of bacterial 
suspension).  The ends of the membrane were heat sealed.  A side-by-side double seal was 
performed at the midpoint of the membrane and the membrane was cut between the inner seals.  
Each exposed end was additionally sealed with liquid bandage drops and dipped in ethanol to 
reduce membrane surface contamination.  Implant membranes were randomly assigned to study 
subjects prior to surgery and stored in PBS overnight at 4º C. 
Anesthesia 
Prior to anesthetic induction, each animal received atropine
F
 (0.02 mg/kg 
intramuscularly) followed by anesthetic induction with an intramuscular injection of an 
acepromazine
G
 (0.5 mg/kg), xylazine
H
 (2 mg/kg), and ketamine
I
 (20 mg/kg) combination.  
                                                 
A
 BD, Franklin Lakes, NJ 
B
 Sigma Aldrich, St. Louis, MO 
C
 Gallenkamp orbital incubator, Sanyo-Gallenkamp, Loughborough, Liecestershire, UK 
D
 Spectronic 20D+, Thermo Scientific Corp., Waltham, MA 
E
 CellMax implant membrane, 500 KDa, Spectrum Laboratories, Rancho Domingo, CA 
F
 Atropine (generic) 15 mg/mL, NeogenVet, Lexington, KY 
G
 Acepromazine (generic) 10 mg/mL, Vedco, Inc., St. Joseph, MO 
H
 Anased 100 mg/mL, Akom, Inc., Decatur, IL 
I
 VetaKet 100 mg/mL, IVX Animal Health, St. Joseph, MO 
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Following induction, an orotracheal tube
J
 was placed and anesthesia was maintained using 
isoflurane
K
 vaporized in 100% oxygen.  Inhalant was administered to maintain surgical 
anesthesia (range 2 to 5 %). Each subject was placed in left lateral recumbency and the surgical 
area was prepared by clipping the hair and performing alternating cycles of iodine
L
 and alcohol
M
. 
Surgical catheterization and placement of implant membranes and ultrafiltration probes    
Using a #10 scalpel
N
, a 10-cm curvilinear skin incision was made beginning at a point 4 
cm cranial and 4 cm lateral to the manubrium and ending 4-cm caudal to the ramus of the 
mandible. The incision was continued through the cutaneous coli muscle and parallel to the 
ventral margin of the sternocephalicus muscle. This muscle was elevated and retracted laterally 
to expose the external jugular vein. The jugular vein and surrounding tissues were lavaged with 
lidocaine
O
 solution to minimize muscular spasm and optimize venous access.   
A 14-gauge hypodermic needle
P
 was used to puncture the jugular vein.  After removal of 
the needle, a 20-cm long, 1-mm diameter silicone rubber tube
Q
 was advanced approximately 8 
cm into the jugular vein.  The phlebotomy site was closed and the catheter secured to the jugular 
vein by imbrication of the adjacent tissues with braided suture
R
.  A Carmalt forceps was used to 
create a tunnel from the dorsal midline approximately 10-cm caudal to the base of the ear and 
exiting deep to the sternocephalicus muscle adjacent to the jugular catheter. The silicone rubber 
tubing was grasped with the Carmalt forceps and pulled through the tissue tunnel.  A luer lock 
                                                 
J
 8mm orotracheal tube, Tyco Healthcare, Pleasanton, CA 
K
 IsoFlo, Abbott Animal health, North Chicago, IL 
L
 Povidone Iodine 7.5%, Triad Disposables, Inc., Brookfield, WI 
M
 Isopropyl alcohol 70%, Barton Solvents, Wichita, KS 
N
 #10 scalpel, Bard-Parker (BD), Franklin Lakes, NJ 
O
 Lidocaine HCl 2%, Hospira, Inc., Lake Forest, IL 
P
 14 x 50 mm, Kendall Monoject, Mansfield, MA  
Q
 Silastic tubing, Dow Corning, Midland, MI 
R
  2-0 Vicryl, Ethicon, Somerville, NJ  
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adapter
S
 was inserted into the tubing to facilitate attachment of an injection port
T
. The catheter 
assembly was thoroughly flushed with heparinized saline (4 USP units heparin
U
 per mL saline
V
 
solution) to ensure patency.  The cutaneous coli muscle was closed with braided suture
W
 in a 
simple continuous pattern and the skin was closed with monofilament suture
X
 in a continuous 
Ford interlocking pattern. Monofilament suture
Y
 was also used to secure the silicone rubber 
tubing at the exit portal by placing a finger trap suture onto the dorsal cervical skin. 
During the same anesthetic event, the implant membranes containing the mixed bacterial 
populations were placed subcutaneously over the right dorsolateral thorax using a subcutaneous 
tunneling needle
Z
.  To implant each membrane, two stab incisions approximately 15 cm apart 
were made using a #22 scapel blade
AA
. The needle was inserted into the caudal incision, tunneled 
through the subcutaneous tissue and exited from the cranial incision.  Any tissue occluding the 
tunneling needle lumen was removed with hemostats.  The implant membrane was placed into 
the lumen of the tunneling needle in retrograde fashion.  The implant membrane was held in 
place at the cranial incision with forceps while the tunneling needle was withdrawn from the 
caudal incision.  The skin incisions were closed with a single simple interrupted suture
BB
.  The 
implantation procedure was repeated until three total membranes were placed in the control 
animals and nine membranes were placed in each of the oxytetracycline treated subjects. 
                                                 
S
 Female luer lock,  
T
 Surflo Luer lock injection port, Terumo Corp., Somerset, NJ 
U
 Heparin 1000 USP/mL, APP Pharmaceuticals, Schaumburg, IL 
V
 0.9% NaCl solution, Baxter Healthcare Corp., Deerfield, IL 
W
 0 Vicryl, Ethicon, Somerville, NJ 
X
 #2 Braunamid, Aesculap Inc., Center Valley, PA 
Y
 #2 Braunamid, Aesculap Inc., Center Valley, PA 
Z
 4.8 (OD) x 3.2mm (ID) skin tunneling needles, Harvard Apparatus, Holliston, MA 
AA
 Miltex Inc., York, PA 
BB
 0 vicryl, Ethicon, Somerville, NJ 
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Two ultrafiltration probes
CC
 were placed subcutaneously in each study animal in the 
dorsal lumbo-sacral area.  The use of the ultrafiltration probes has been described in detail 
elsewhere
2.  A two incision method was used as per manufacturer‟s instructions.  The vacuum 
vial holders were anchored to the study animals by direct suturing with monofilament suture
DD
.   
An aural catheter was placed for subjects in the intravenous treatment group prior to 
discontinuation of anesthesia.  Following sterile preparation, the auricular vein was distended by 
occlusion and a catheter
EE
 was placed.  Following placement, the catheter was capped, flushed, 
and locked with heparinized saline solution.  The aural catheter was then secured to the ear with 
surgical glue and elastic tape. 
Upon completion of the surgical procedures, the isoflurane was discontinued while the 
animal remained on 100% oxygen for a brief period.  The animal was removed from the semi-
circle breathing system and returned to its holding stall.  The animal was monitored until 
removal of the endotracheal tube, and a 4 hr recovery period was observed prior to treatment 
administration. 
Oxytetracycline administration 
The drug formulation used for this study contained 200 mg oxytetracycline base per mL 
as the dihydrate form in 2-pyrrolidone and povidone
FF
.  Oxytetracycline was administered 
following the 4 hour post-surgery recovery period.  Subjects in the intravenous treatment group 
received 8 mg/kg of oxytetracycline via the aural catheter.  Following drug administration, the 
catheter was flushed with heparinized saline and removed immediately. 
                                                 
CC
 UF-3-12 Ultrafiltration probe, BASi, West Lafayette, IN 
DD
 0 Braunamid, Aesculap Inc., Center Valley, PA 
EE
 22 ga x 25 mm catheter, Nipro Corp., Osaka, Japan 
FF
 Liquamycin LA-200, Pfizer Animal Health, New York, NY 
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For intramuscular injection, 12 mg/kg of oxytetracycline was administered in the 
semimembranosus / semitendinosus area using an 18G. x 25 mm needle.  Treatment was 
administered in the hindlimb contralateral to the one used for pre-anesthetic solution injection. 
Doses were chosen based on pharmacokinetics from a preliminary study in animals of 
similar age/production status. 
Plasma Sampling 
Blood samples were collected by syringe from the jugular catheter immediately prior to 
oxytetracycline administration and at 0.25, 0.5, 1, 1.5, 2, 4, 6 and 12 hours after oxytetracycline 
administration.  The samples were placed in a lithium heparin tube
GG
 and placed on ice.  For 
further processing, the samples were centrifuged at 2350 x g for 5 minutes.  The plasma was 
extracted from the sample using a transfer pipette
HH
 and placed in a labeled cryovial
II
.  Processed 
samples were stored at -70 C until analysis. 
Interstitial Fluid (ISF) Sampling 
Interstitial fluid collection has been described previously
3
.  Interstitial fluid samples were 
collected from the ultrafiltration probes at 2 hour intervals.  At each timepoint, the collected ISF 
from the two probes in each animal was pooled.  Interstitial fluid collected during the pre-
treatment recovery period for all subjects and from the control animals during the entire study 
was pooled and used for blank matrix during drug analysis.  Samples collected from treated 
animals were transferred to cryovials using a calibrated pipette
JJ
.  To estimate sample volume, 
collected fluid was pipetted in 50 µL increments with rounding to the nearest 25 µL. 
                                                 
GG
 3 mL Vacuette LiHep, Greiner bio-one, Monroe, NC 
HH
 Fisherbrand transfer pipettes, Fisher Scientific, Pittsburgh, PA 
II
 2 mL cryogenic vial, Fisher Scientific, Pittsburgh, PA 
JJ
 EDP2, Rainin Instrument Co., Oakland, CA 
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Oxytetracycline quantification in plasma 
The procedures / conditions for sample preparation and analysis have been detailed in 
Chapter 2.  Blank swine plasma was used to construct the standard curve, which consisted of 6 
non-zero points.  The standards were fit to a quadratic curve across the range of concentrations 
(20 ng/mL [LLOQ] to 14,000 ng/mL).  The run was accepted if the concentrations were within 
15% of the expected concentration and the fit of the standard curve was at least 0.999.  Accuracy 
and coefficient of variation for the quality control samples were ± 3.6% and <5%, respectively. 
Oxytetracycline quantification in interstitial fluid 
The procedures / conditions for sample preparation and analysis are as above with the 
exception of the matrix used.  Interstitial fluid collected from the 3 control animals served as the 
matrix for the standard curve.  The standard curve, constructed from 7 non-zero points, was 
quadratic across the range of concentrations (20 ng/mL (LLOQ) to 14,000 ng/mL).  The run was 
accepted if the standard concentrations were within ± 15% of the expected concentration and the 
fit of the standard curve was at least 0.999.  Accuracy and coefficient of variation for the quality 
control samples were ± 6.0% and <3%, respectively. 
Oxytetracycline concentration in implant membranes 
Following removal of the implant membranes, the nine straws were divided into 3 pools.  
The contents of each pool were placed into a centrifuge vial and spun at 5000 x g for 10 minutes.  
The supernatant was collected for oxytetracycline quantification and the pellet was collected for 
quantification of Salmonella, E. coli, and transconjugant populations.  Thus, 3 replicates of 
bacterial and oxytetracycline quantification were performed per treated animal subject.  The 
contents of the 3 implant membranes in the control subjects were not pooled and were used for 
bacterial quantification only.  Implant membrane and interstitial fluid samples were analyzed 
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concurrently, utilizing the same standards constructed from blank porcine interstitial fluid.   The 
accuracy and coefficient of variation for the quality control samples were ± 6.0% and <3%, 
respectively. 
 Protein binding 
Protein binding was determined in porcine plasma by ultrafiltration / centrifugation.  
Triplicate aliquots (200 uL) of the low (20 ng/mL), medium (500 ng/mL) and high (14000 
ng/mL) calibration solutions from the standard curve were pipetted into centrifugal filtration 
vials
KK
.  The vials were centrifuged at 14,000 x g for 30 minutes.  The preparation and 
quantification procedures were as detailed in Chapter 2.   
The standard curve for protein binding in porcine plasma was fit with a quadratic 
equation consisting of 7 points across the range of concentrations.  Accuracy was within ± 8.2% 
of expected concentrations for plasma.  Protein binding was calculated by dividing the 
concentration of the filtered / centrifuged sample by the concentration in the unfiltered standard.  
The percent free drug was averaged for the 9 samples (3 replicates at 3 concentrations).  
Protein binding was also determined in brain-heart infusion broth by ultrafiltration / 
centrifugation.  Triplicate aliquots (200 uL) of the low (20 ng/mL), medium (500 ng/mL) and 
high (14000 ng/mL) calibration solutions from the standard curve were pipetted into centrifugal 
filtration vials
LL
.  The vials were centrifuged at 14,000 x g for 30 minutes.  The standard curve 
for protein binding estimate was fit with a quadratic equation consisting of 6 points across the 
range of concentrations.  Accuracy was within ± 3% of expected concentration.  Protein binding 
was calculated using equation 4 (Chapter 2).   
                                                 
KK
 Microcon YM-10, Millipore Corp., Bedford, MA 
LL
 Microcon YM-10m, Millipore Corp., Bedford, MA 
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Bacterial quantification & determination of plasmid transfer 
The procedures for bacterial quantification and calculation of transconjugation rates were 
as reported in Chapter 3.  Briefly, contents of the in situ membranes were centrifuged at 5,000 x 
g for 10 minutes.  The supernatant was collected and the pellet resuspended.  An aliquot of the 
bacterial suspension was serially diluted in 10 fold increments.  Plating the serial dilutions on 
selective media allowed for quantification of the donor and transconjugant populations.  Data are 
reported as the transconjugant ratio (Equation 7, Chapter 3).    
Study termination 
Based on the in vitro experiments detailed in Chapter 3, the plasmid transfer rates were 
highest at the 12 hour time point.  Implant membranes were removed after the subjects were 
euthanized by barbiturate
MM
 overdose following the 12 hour plasma and interstitial fluid time 
points.  The implant membranes were carefully dissected from their subcutaneous sites and 
placed in tubes of PBS for bacterial quantification (all subjects) and oxytetracycline analysis 
(treated subjects only). 
Pharmacokinetic Analysis 
Oxytetracycline concentrations in the plasma were corrected for protein binding.  Free 
drug concentrations (plasma and ISF) were analyzed by noncompartmental analysis using 
commercial pharmacokinetic software.  For the interstitial fluid samples, concentrations were 
analyzed as representing the midpoint of the two hour collection period. 
 
 
                                                 
MM
 Fatal Plus, Vortech Pharmaceuticals, Dearborn, MI 
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Statistical Analysis 
All statistical analyses were performed using a commercial statistical package
NN
.  Using 
the generalized linear model procedure, analysis of variance was performed with treatment (IV, 
IM or control) as the independent variable and transconjugant ratio (logarithmically (base 10) 
transformed) as the dependent variable.  The subject that received subcutaneous oxytetracycline 
was included in the intramuscular treatment group. 
For the linear regression analysis, the transconjugant ratios (logarithmically (base 10) 
transformed) were regressed against 5 pharmacokinetic parameters; the unbound concentrations 
of oxytetracycline in the implant membranes, plasma observed maximal concentration (Cmax), 
ISF observed Cmax, area under the plasma concentration time curve (AUCobserved), and ISF 
AUCobserved.  The null hypothesis to be rejected was that there is no correlation (regression slope 
= 0) between the transconjugant ratio and drug exposure parameters.   
Results 
Protein binding of oxytetracycline in swine plasma was linear across the concentration 
range of the standard curve.  A mean free drug proportion of 42% across the concentration range 
of the standard curve was determined.  This is similar to other published estimates of 
oxytetracycline plasma protein binding in swine
4
.  Estimates of protein binding in the implant 
membranes were between 13-19%, therefore all concentrations were adjusted to free drug based 
on equation 4 (Chapter 2). 
Oxytetracycline administration was perivascular in one subject in the intravenous 
treatment group.  Pharmacokinetics from this animal confirmed this and the subject was analyzed 
                                                 
NN
 SAS 9.3.1, SAS Institute, Cary, NC 
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using an extravascular input model.  See Table 6 for individual animal pharmacokinetics in 
plasma and ISF.  
Free drug concentrations within the implant membranes were well correlated to 
oxytetracycline concentrations in the interstitial fluid at the last sampling interval for the 
parenteral administrations (R
2
= 0.86, Figure 13).  The correlation was negatively affected by 
inclusion of the IV treated animals due to higher concentrations in the implant membranes 
compared to ISF. (Figure 14). 
There was no statistical difference in the transconjugant ratios between treatment groups 
in the analysis of variance (p=0.747).  The linear regression analysis showed that none of the 
pharmacokinetic parameters in either plasma or ISF were significantly correlated to 
transconjugant ratio (Figures 16-19).  All calculated measures of drug exposure in this model 
were poorly correlated to plasmid transfer within the implant membranes at 12 hours, as 
evidenced by p-values greater than 0.797 for all regression analyses.   
Discussion 
There is a growing body of research describing the correlation of results from in vitro 
pharmacodynamic models to in vivo studies.  In a study by Aviles et al.
5
, fungal response in the 
IVPM was well correlated (R
2
 =0.995) to the response seen in an immunocompetent murine 
sepsis model when free drug concentrations were used.  In a study by Den Hollander et al.
6
, in 
vitro and in vivo dose fractionation studies were performed to determine the optimal PK/PD 
index for azithromycin.  However, the authors noted some discrepancy in the bacterial responses 
between the two models used.  In the IVPM, the single dose resulted in a significantly greater 
CFU reduction at 6 hrs than the fractionated doses.  In the murine sepsis/peritonitis model, 
bacterial response was similar for both dosing regimens.  However, survival was not well 
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correlated to bacterial counts in vivo.  When the bacterial response in vitro and survival rates in 
vivo were used to determine the optimal PK/PD index for azithromycin, Cmax was shown to be 
most predictive of antimicrobial efficacy in both models. The authors contributed the lack of 
correlation in bacterial responses to differences in growth rates between the two models.   
Blaser, et al.
7
 also demonstrated good correlation between the IVPM and a tissue cage 
model in guinea pigs for a multitude of antimicrobial-pathogen combinations.  Greko, et al., 
were able to correlate danofloxacin efficacy to AUC:MIC ratio in a tissue cage model in calves
8
.  
This agrees with other PK/PD literature for fluoroquinolones
9,10
.  However, in this model the 
bacterial inoculum and antimicrobial were both administered directly into the tissue cage.   
The results of the present in situ study are compared to previous results by the authors 
utilizing an in vitro pharmacodynamic model (IVPM)
11
 incorporating the same bacterial isolates 
and antimicrobial.  In the previous study, the rate of horizontal gene transfer between these two 
bacterial strains was suppressed when antimicrobial concentrations exceeded the MIC of the 
recipient bacteria.  In the present study, the analysis of variance demonstrated no statistical 
difference in the transconjugant ratios between treated and control animals.  In the regression 
analysis, the transconjugant ratio in the implant membranes at 12 hours was not correlated to any 
of the measures of drug exposure examined.  Additionally, the y-intercept for the regression 
analyses of the treated animals was approximately -7.3.  This is equivalent to the average log 
transconjugant ratio of the bacteria in the control subjects.  In comparison, the previous in vitro 
study found log transconjugant ratios at 12 hours were -5.6 and -6.2 for the untreated controls.  
This discrepancy may be partially explained by the sample timing; the period from inoculation to 
treatment administration was slightly different in the two studies.  The 12 hour time point in situ 
is the time from treatment administration.  In the in vitro model, the bacterial populations were in 
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logarithmic growth prior to inoculation into the model, followed by a one hour growth period.  In 
the in situ model, bacterial populations were prepared and placed in the implant membranes, then 
stored at 4º C overnight.  The membranes were removed from refrigeration as the individual 
animal underwent the surgical procedure, followed by a 4 hour recovery period.  Thus, the age of 
the bacterial populations between the two experiments were also different and may partly explain 
the results reported here.     
Inherent in vitro – in situ differences may in part explain the results in plasmid transfer 
ratios.  In the in vitro experiment, conditions (media, temperature and lack of immune response) 
are ideally suited to the bacteria.  However, conditions are quite different in vivo.  Although the 
in situ implant membrane should limit the influence of immunity through size exclusion of host 
factors, the nutrient influx from interstitial fluid into the bacterial broth may create a less optimal 
growth environment for plasmid transfer as compared to the constant influx of growth media in 
the in vitro model.  This may be especially true for laboratory strains that may have lost 
virulence factors enabling infection in an animal host.  If resistance transfer is limited to baseline 
levels in situ for these reasons, further suppression may not be evident in the present study 
design.   
The membranes themselves may also be a limiting factor to transconjugation.  The 
volume of the membrane limits the absolute number of bacteria that can be placed in close 
proximity for a contact related event (conjugation), and may therefore be a limiting factor for 
plasmid transfer.  
Another potential explanation for the lack of correlation is difference in drug exposure. 
Oxytetracycline concentrations in the implant membranes were measured at only one time point 
(12 hour); however, all concentrations within the membrane exceeded the inhibitory 
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concentration of the recipient bacteria.  Based on previous results, these concentrations should be 
sufficient to suppress plasmid transfer.  Additionally, because the correlation between ISF 
oxytetracycline concentrations and implant membrane concentrations was good for parenteral 
treatment, the assumption, at least for this group of study subjects, is that implant membrane 
exposure would be similar to ISF concentrations.   
Although previous experiments in vitro did not show diffusion to be a limiting factor 
(Appendix B), the poorer correlation for IV treated subjects may be a result of diffusional lag 
across the implant membrane.  The peak plasma concentrations reported for the IV treated 
animals were similar to the in vitro concentrations of oxytetracycline in the study reported in the 
appendix; however, the concentration gradient in the present study would have been reduced 
more rapidly due to in vivo elimination compared to in vitro degradation in the study in the 
appendix.  The reduced gradient in vivo could result in lower oxytetracycline concentrations in 
the implant membranes.  Perhaps the correlation between drug exposure and horizontal gene 
transfer would be improved by using different measures of drug exposure.  In the present study, 
only the traditional PK/PD measures were correlated to the transconjugant ratio.  
A significant limitation to this study is the terminal sampling of the implant membranes.  
The 12 hour time point was chosen as the optimal sampling time based on in vitro work reported 
previously.  If the time of maximal plasmid transfer occurs at a time other than 12 hours due to 
discussed differences in situ, then effects of drug exposure may not be evident with the current 
study design.  Although actual transconjugant ratios in vitro and in situ were slightly different, it 
is important to note that at no time during either experiment were transconjugant ratios enhanced 
in the oxytetracycline exposed bacterial populations compared to respective controls.   
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The results of the present study provide an in vitro – in situ correlation for the effects of 
oxytetracycline exposure on transfer of antimicrobial resistance plasmids.  Future studies are 
needed to address the limitations of the in situ model and to validate the preliminary findings of 
the present study.   
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Figures and Tables 
 
Table 6: Pharmacokinetic parameters for individual animal subjects 
 
Animal ID 
 
Treatment 
Plasma ISF 
fCmax 
µg/mL 
fAUC 
hr*µg/mL 
fCmax 
µg/mL 
fAUC 
hr*µg/mL 
31 Intramuscular 0.99 8.91 0.96 8.80 
38 Intramuscular 0.75 5.36 0.79 6.64 
33 Intramuscular 0.72 5.90 0.77 6.17 
Mean ± SD Intramuscular 0.82 ± 0.15 6.72 ± 1.91 0.84 ± 0.10 7.20 ± 1.40 
37 Intravenous 3.32 13.19 1.81 13.75 
32 Intravenous 5.17 13.72 2.57 16.56 
Mean ± SD Intravenous 4.25 ± 1.31 13.46 ± 0.37 2.19 ± 0.54 15.16 ± 1.99 
35 Intravenous** 0.41 4.15 0.41 2.73 
 
** Pig #35 – Administration was perivascular due to loss of aural catheter.  Animal was modeled 
using a non-compartmental extravascular input model. 
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Figure 10:  Correlation of Interstitial Fluid and Implant membrane oxytetracycline 
concentrations in IM/SC treated animals 
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Figure 11:  Correlation of Interstitial Fluid and Implant membrane oxytetracycline 
concentrations in all treated animals 
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Figure 12:  Correlation of free oxytetracycline in implant membranes to Transconjugant 
ratio (log10) 
y = -6E-05x - 7.3053
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P value tests: Ho: slope = 0 [no correlation between independent and dependent variables] 
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Figure 13: Correlation of Interstitial fluid AUC to Transconjugant ratio (log10) 
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P value tests: Ho: slope = 0 [no correlation between independent and dependent variables] 
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Figure 14: Correlation of Interstitial fluid Cmax to Transconjugant ratio (log10) 
y = 0.0253x - 7.3781
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P value tests: Ho: slope = 0 [no correlation between independent and dependent variables] 
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Figure 15: Correlation of Plasma AUC to Transconjugant ratio (log10) 
y = 0.0052x - 7.3919
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P value tests: Ho: slope = 0 [no correlation between independent and dependent variables] 
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Figure 16: Correlation of Plasma Cmax to Transconjugant ratio (log10) 
y = 0.0097x - 7.3657
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P value tests: Ho: slope = 0 [no correlation between independent and dependent variables] 
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Appendix A - Considerations for future studies 
The primary focus of this research was the development and utilization of an in vitro 
pharmacodynamic model.  During the model development stage, many lessons were learned 
concerning the nuances of in vitro pharmacodynamic models.  Included here is a brief discussion 
of the encountered problems to serve as a guide for future work in this field of study.   
Contamination of the in vitro Pharmacodynamic Model 
Our initial experimental runs in the two compartment model suffered from contamination 
of the central and fresh media reservoirs.  Four simple procedural changes reduced the 
contamination rates significantly.  The central reservoir was autoclaved with the media in place.  
This decreases the number of media transfers to only the transfer of media into the fresh 
reservoir.  Autoclaving the fresh media in place was considered but not implemented because the 
fresh media reservoirs were not compatible with extended autoclave times.  Due to the large 
volumes of media being sterilized in each jar (2 L), autoclave time was increased from the 
recommended 15 minutes to 1 hour.  System assembly was originally done in an open-faced 
biosafety hood, but was moved to a larger biosafety cabinet; decreasing the potential for 
contamination of the system due to exposure to the personnel assembling the setup.  The larger 
size cabinet also allowed all components to be placed inside prior to assembly, thus preventing 
the breaks in sterile technique associated with the smaller biosafety hood.  The final change that 
effected contamination reduction was implementing the use of aluminum foil “caps” on any 
exposed port prior to autoclaving.  These caps could then be individually removed during 
assembly.   
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The transition to the one-compartment model also had an impact on the contamination of 
the assembled system.  The one-compartment model consists of fewer components and thus 
results in fewer potential instances for contamination.  Although no contaminant bacteria were 
noted during the plate counting, it is possible that low levels of contamination would be 
overcome by competitive exclusion due to the large inoculum of P. multocida (Chapter 2) and E. 
coli and Salmonella (Chapter 3). 
Drug Loss 
One of the primary limitations to the interpretation of data in Chapter 2 was the failure to 
achieve the desired pharmacokinetics in the in vitro pharmacodynamic model.  The achieved 
targets were less than desired in all replicates.  The following discussion addresses each of the 
contributing factors to undesired loss of oxytetracycline individually. 
Drug Binding 
Prior to utilizing the model described here, a capillary (two-compartment) in vitro 
pharmacodynamic model had been utilized by the author.  The core components of the model 
were as for the one-compartment model with the addition of a hollow fiber (HF) capillary 
module
A
.  The bacterial culture was inoculated into the extracapillary space of the HF module.  
Media from the central reservoir was circulated through the HF module by a peristaltic pump 
specifically designed for use with this module.  Pharmacokinetic analysis of data obtained from 
this model setup showed an absorption phase, which was problematic due to the fact that the 
dosing simulation was for an intravenous bolus.  We hypothesized that either the drug was not 
being circulated from the central reservoir rapidly enough or that oxytetracycline was binding to 
                                                 
A
 Medium 20 kD cartridge, Fibercell Systems, Fredrick, Maryland. 
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the polysulfone fibers and not diffusing into the extracapillary space.  The circulating pump was 
set at its highest setting, therefore we attempted to circumvent the issue of circulation/diffusion 
by using higher concentrations of oxytetracycline in the central reservoir.  After several attempts 
without successfully achieving the target pharmacokinetics, the more simple one-compartment 
model described here was adopted. 
In the one-compartment model, potential issues with oxytetracycline binding continued.  
However, because of the simplicity of the model only two components contacted the central 
reservoir media, and only the glass reservoir itself and the stir rod were investigated.  The 
experimental investigation into sources of drug loss is described below.   
Drug Degradation 
Another consideration for the failure to reach desired pharmacokinetic targets in the in 
vitro model is degradation.  Three potential sources of degradation: enzymatic (media enzymes 
or bacterial enzymes), temperature, and ultraviolet radiation were considered.     
A similar loss with respect to oxytetracycline was described by Bergan.
1
  Under the 
conditions of the study (Mueller-Hinton broth (MHB) at 37° C), the estimated half-life of 
degradation was approximately 3 hrs.  In 2008, Loftin et al.
2
 studied the degradation rates of 
oxytetracycline and other antibiotics under various conditions of temperature, ionic strength and 
pH.  Although the authors failed to state the starting concentration of oxytetracycline used, the 
estimated half-life of degradation at 35° C, pH = 7 was 19 hours (effects from changes in 
osmolality were insignificant). 
In an experiment to test the stability of oxytetracycline in brain-heart infusion broth at 
37° C, we found that oxytetracycline degrades with an approximate half-life of 23.8 hours
3
.  This 
is quite similar to the findings of Loftin et al. described above and stability estimates (26 hrs 
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under similar conditions) reported in the drug monograph
4
.  Differences in growth media and 
analytic methods could potentially explain the contrasting results of Bergan et al.  In our 
experiment, brain-heart infusion broth (BHI) was used; Loftin et al. used an aqueous solution of 
sodium monohydrogen phosphate while Bergan used Mueller-Hinton broth.  No enzymes would 
be expected in the aqueous solution, while there could be enzymes in the MHB that were not 
present in the BHI, resulting in a faster degradation.  In both the present study and the Loftin 
study, an LC/MS method was used, while Bergan used a microbiological assay for quantifying 
drug concentration.  Since the assay requires further incubation and oxytetracycline is heat-
labile, then the extended time at higher temperature could result in falsely decreased 
concentrations and a shorter half-life.  The implication of these findings is that oxytetracycline 
concentrations in vitro are NOT static under the conditions required for bacterial growth.  This 
must be recognized when making comparisons to antimicrobials that are temperature/pH stable. 
System Costs 
In vitro pharmacokinetic model research can be very expensive to conduct.  In addition to 
the basic equipment required (incubator, pumps, reservoirs, and tubing), there are significant 
disposable costs associated with each experimental run.  Because the hollow fiber modules are 
by far the most expensive disposable item, transitioning to or starting with a one-compartment 
model will reduce operating expenses.  There are two potential means of reducing system costs:  
reducing system size and reducing the number of control runs.  If the size of the central reservoir 
is reduced, fresh media volumes will also be reduced for an identical half-life simulation.  This 
was not implemented in our system as we had previously purchased pumps and reservoir caps 
sized for the two compartment pharmacodynamic model.  
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Reducing the number of control arms should be given serious consideration.  If a 
traditional dose fractionation experiment is being performed with identical half-lives for both 
treatments, then one control arm is easily eliminated as the remaining control will suffice for 
both treatments.  However, not utilizing at least one concurrent control arm may lead to 
questions regarding the inter-run variability in the bacterial populations. 
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Appendix B - Implant membrane oxytetracycline diffusion 
Experimental objective / hypothesis 
A preliminary experiment was performed to assess issues relating to use of implant 
membranes within the in vitro pharmacodynamic model.  If the implant membranes could be 
utilized within the IVPM, an additional variable could be eliminated from the in vitro – in vivo 
correlation.  The research hypothesis was that oxytetracycline concentrations within the implant 
membranes were not limited by diffusion and/or drug binding.   
Materials and Methods 
Implant membranes were cut to approximately 75 mm segments.  Thirty–six segments 
were filled with sterile BHI and heat sealed as previously described in Chapter 3.  Porous cages 
were fabricated from 10 x 75 mm plastic test tubes. Three implant membrane segments were 
placed in each plastic cage and stored in sterile PBS at 4° C overnight. 
Three reservoirs containing 500 mL of sterile brain–heart infusion broth were placed in 
the incubator.  Four plastic cages containing the implant membrane segments were placed in 
each reservoir.  Oxytetracycline base (1mg/mL) was added to each reservoir resulting in a 
starting concentration of 8.8 µg/mL.  At 2, 4, 8, and 12 hours after the oxytetracycline was 
added, one cage was removed from each of the replicate reservoirs.  The ends of the implant 
membrane were cut and the media collected in a 2 mL cryovial.  All samples were stored at -80° 
C until analysis. 
Samples were prepared by the solid phase extraction method, and analyzed by 
LC/MS/MS method described in Chapter 2 for oxytetracycline in brain-heart infusion broth.  The 
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standard curve consisted of 6 non-zero points ranging from 20 ng/mL to 14000 ng/mL.  The run 
was accepted if the concentrations of the standards were within 15% of the expected 
concentration and the fit of the curve was at least 0.99.  Two low (350 ng/mL) and two medium 
(6000 ng/mL) quality controls were run; one low QC was < 20% of the expected value and was 
excluded.  The accuracy and coefficient of variation of the remaining QC samples were ± 19% 
and ± 17%, respectively. 
The results were analyzed statistically by timepoint using one-way ANOVA to test the 
hypothesis that implant membrane concentration was equal to media concentration at each time 
point. 
Results and Discussion 
One time point in the implant membranes (2 hr) was not analyzed due to insufficient 
sample volume.  Although the other time points contained sufficient volume for analysis, the 
number of implant membranes needed to provide this volume was problematic given the size of 
the central reservoir used in the present study.   
The comparison of media to implant membrane concentration is presented in Figure 16.  
Oxytetracycline concentrations were not statistically different between the media and implant 
membranes at 2, 4, and 8 hrs.  Concentrations were significantly less in the implant membranes 
at 12 hours (p=0.01).  If the disparity in concentrations in media and implant membranes were a 
diffusion related phenomenon, it would be expected that differences would be seen across time 
points as the average concentration was approximately 4000 ng/mL for the duration of the 
experiment.  One diffusion related explanation for the discrepancy at 12 hours is that the implant 
membranes would float near the surface of the broth as the experiment progressed.  If the 
membranes were not fully immersed in the media, surface area of the membrane would be 
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reduced and diffusion limited.  This would be more pronounced at latter time points because the 
multiple cages present initially would have to be placed on end to fit within the IVPM, however 
as cages were removed remaining cages tended to float sideways.   
Ultimately, the use of the implant membranes within the IVPM was abandoned due to the 
inability to maintain a sterile IVPM during repeated extraction of implant membranes from the 
central reservoir at multiple time points. 
The use of a sepsis model in vitro (Chapter 3) and in situ model (Chapter 4) represents a 
variable that cannot be accounted for in this research.  Because the effects of drug exposure on 
plasmid transfer were different in the two studies, this represents on area of improvement in 
future studies.  The lack of agreement between these models should be investigated further 
before either model is pronounced superior.   
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Figure 17:  Implant membrane and media concentrations in the in vitro pharmacodynamic 
model at 2, 4, 8 and 12 hours 
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** Same symbols represents paired (membrane – media) samples from the same replicate 
** Implant membrane concentrations are blue 
** Media concentrations are red 
** One implant membrane sample at 2 hours was not analyzed due to insufficient sample volume 
 
 
